Death	B-GP
receptor	I-GP
6	I-GP
contributes	O
to	O
autoimmunity	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG

Expansion	O
of	O
autoreactive	O
follicular	O
helper	O
T	O
(	O
Tfh	O
)	O
cells	O
is	O
tightly	O
restricted	O
to	O
prevent	O
induction	O
of	O
autoantibody	O
-	O
dependent	O
immunological	B-DS
diseases	I-DS
,	O
such	O
as	O
systemic	B-DS
lupus	I-DS
erythematosus	I-DS
(	O
SLE	B-DS
).	O

Here	O
we	O
show	O
expression	O
of	O
an	O
orphan	O
immune	O
regulator	O
,	O
death	B-GP
receptor	I-GP
6	I-GP
(	O
DR6	B-GP
/	O
TNFRSF21	B-GP
),	O
on	O
a	O
population	O
of	O
Tfh	O
cells	O
that	O
are	O
highly	O
expanded	O
in	O
lupus	B-DS
-	O
like	O
disease	O
progression	O
in	O
mice	B-OG
.	O

Genome	O
-	O
wide	O
screening	O
reveals	O
an	O
interaction	O
between	O
syndecan	B-GP
-	I-GP
1	I-GP
and	O
DR6	B-GP
resulting	O
in	O
immunosuppressive	O
functions	O
.	O

Importantly	O
,	O
syndecan	B-GP
-	I-GP
1	I-GP
is	O
expressed	O
specifically	O
on	O
autoreactive	O
germinal	O
centre	O
(	O
GC	O
)	O
B	O
cells	O
that	O
are	O
critical	O
for	O
maintenance	O
of	O
Tfh	O
cells	O
.	O

Syndecan	B-GP
-	I-GP
1	I-GP
expression	O
level	O
on	O
GC	O
B	O
cells	O
is	O
associated	O
with	O
Tfh	O
cell	O
expansion	O
and	O
disease	O
progression	O
in	O
lupus	B-DS
-	O
prone	O
mouse	B-OG
strains	O
.	O

In	O
addition	O
,	O
Tfh	O
cell	O
suppression	O
by	O
DR6	B-GP
-	O
specific	O
monoclonal	O
antibody	O
delays	O
disease	O
progression	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

These	O
findings	O
suggest	O
that	O
the	O
DR6	B-GP
/	O
syndecan	B-GP
-	I-GP
1	I-GP
axis	O
regulates	O
aberrant	O
GC	O
reactions	O
and	O
could	O
be	O
a	O
therapeutic	O
target	O
for	O
autoimmune	B-DS
diseases	I-DS
such	O
as	O
SLE	B-DS
.	O

Germinal	O
centre	O
(	O
GC	O
)	O
reactions	O
are	O
driven	O
by	O
T	O
follicular	O
helper	O
(	O
Tfh	O
)	O
cells	O
and	O
their	O
dysregulation	O
can	O
cause	O
autoimmune	B-DS
disease	I-DS
.	O

Here	O
the	O
authors	O
show	O
that	O
the	O
orphan	O
receptor	O
DR6	B-GP
is	O
a	O
Tfh	O
cell	O
marker	O
that	O
binds	O
syndecan	B-GP
-	I-GP
1	I-GP
on	O
GC	O
B	O
cells	O
driving	O
autoimmunity	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

Systemic	B-DS
lupus	I-DS
erythematosus	I-DS
(	O
SLE	B-DS
)	O
is	O
a	O
chronic	B-DS
inflammatory	I-DS
disease	I-DS
resulting	O
from	O
autoantibody	O
recognition	O
of	O
self	O
-	O
antigens	O
,	O
with	O
autoantibody	O
production	O
dependent	O
on	O
activation	O
of	O
autoreactive	O
T	O
and	O
B	O
cells1	O
.	O

Although	O
autoreactive	O
T	O
and	O
B	O
cells	O
can	O
be	O
detected	O
in	O
healthy	O
wild	O
-	O
type	O
mice23	B-OG
,	O
the	O
expansion	O
and	O
activation	O
of	O
these	O
cells	O
are	O
tightly	O
controlled	O
by	O
tolerance	O
mechanisms	O
.	O

Defects	O
in	O
genes	O
associated	O
with	O
apoptotic	O
cell	O
clearance	O
cause	O
systemic	B-DS
autoimmune	I-DS
disease	I-DS
in	O
familial	O
SLE	B-DS
patients	O
and	O
C57BL	B-OG
/	I-OG
6	I-OG
(	I-OG
B6	I-OG
)	I-OG
mice456	I-OG
.	O

Normally	O
,	O
the	O
activation	O
of	O
autoreactive	O
lymphocytes	O
should	O
be	O
regulated	O
at	O
the	O
stage	O
of	O
initial	O
T	O
/	O
B	O
cell	O
interactions789	O
.	O

The	O
activation	O
and	O
differentiation	O
of	O
peripheral	O
T	O
and	O
B	O
cells	O
requires	O
multiple	O
steps10	O
.	O

Antigen	O
-	O
primed	O
CD4	B-GP
+	O
T	O
cells	O
migrate	O
from	O
the	O
T	O
cell	O
zone	O
to	O
the	O
B	O
cell	O
follicles	O
after	O
expressing	O
CXCR5	B-GP
,	O
which	O
is	O
a	O
chemokine	O
receptor11	O
.	O

In	O
the	O
lymphoid	O
structure	O
termed	O
the	O
germinal	O
centre	O
(	O
GC	O
),	O
located	O
on	O
the	O
border	O
between	O
the	O
T	O
and	O
B	O
cell	O
zones	O
,	O
the	O
primed	O
CD4	B-GP
+	O
T	O
cells	O
differentiate	O
into	O
follicular	O
helper	O
T	O
(	O
Tfh	O
)	O
cells	O
and	O
promote	O
B	O
cell	O
maturation	O
,	O
such	O
as	O
proliferation	O
,	O
somatic	O
hyper	O
maturation	O
and	O
immunoglobulin	B-GP
class	O
switching	O
,	O
through	O
its	O
production	O
of	O
cytokines	B-GP
such	O
as	O
interleukin	B-GP
(	B-GP
IL	I-GP
)-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
21	I-GP
.	O

Tfh	O
cells	O
express	O
the	O
chemokine	B-GP
receptor	I-GP
CXCR4	B-GP
to	O
migrate	O
from	O
the	O
original	O
follicle	O
to	O
a	O
neighboring	O
follicle	O
and	O
induce	O
new	O
GC	O
formation	O
.	O

In	O
these	O
sequential	O
steps	O
,	O
reciprocal	O
signals	O
by	O
antigen	O
-	O
specific	O
GC	O
B	O
cells	O
are	O
important	O
for	O
complete	O
Tfh	O
cell	O
differentiation	O
and	O
maintenance	O
.	O

In	O
promoting	O
complete	O
Tfh	O
cell	O
differentiation	O
,	O
the	O
GC	O
B	O
cells	O
activate	O
T	B-GP
cell	I-GP
receptor	I-GP
(	O
TCR	B-GP
)	O
signalling	O
through	O
antigen	O
presentation	O
.	O

The	O
expression	O
of	O
costimulatory	O
ligands	O
such	O
as	O
inducible	B-GP
T	I-GP
cell	I-GP
co	I-GP
-	I-GP
stimulator	I-GP
ligand	I-GP
(	O
ICOSL	B-GP
)	O
and	O
programmed	B-GP
cell	I-GP
death	I-GP
-	I-GP
1	I-GP
ligand1	I-GP
/	O
2	O
(	O
PD	B-GP
-	I-GP
L1	I-GP
/	O
2	O
)	O
on	O
GC	O
B	O
cells	O
regulates	O
TCR	B-GP
signal	O
activation	O
,	O
both	O
positively	O
and	O
negatively12	O
.	O

Notably	O
,	O
a	O
functional	O
blockade	O
or	O
defect	O
in	O
negative	O
costimulatory	O
molecules	O
,	O
including	O
programmed	B-GP
cell	I-GP
death	I-GP
1	I-GP
(	O
PD1	B-GP
)	O
or	O
cytotoxic	B-GP
T	I-GP
-	I-GP
lymphocyte	I-GP
-	I-GP
associated	I-GP
protein	I-GP
4	I-GP
(	O
CTLA4	B-GP
),	O
induces	O
an	O
aberrant	O
GC	O
reaction	O
and	O
systemic	B-DS
autoimmunological	I-DS
disease13141516	I-DS
.	O

These	O
findings	O
indicate	O
that	O
during	O
T	O
/	O
B	O
cell	O
interactions	O
,	O
costimulatory	O
molecules	O
fine	O
-	O
tune	O
Tfh	O
cell	O
differentiation	O
,	O
thus	O
preventing	O
the	O
induction	O
of	O
systemic	O
autoimmunity	O
.	O

Death	B-GP
receptor	I-GP
6	I-GP
(	O
DR6	B-GP
/	O
CD358	B-GP
)	O
is	O
also	O
known	O
as	O
tumour	B-GP
necrosis	I-GP
factor	I-GP
(	I-GP
TNF	I-GP
)	I-GP
receptor	I-GP
superfamily	I-GP
member	I-GP
21	I-GP
(	O
TNFRSF21	B-GP
)	O
17	O
.	O

The	O
TNFRSF	B-GP
includes	O
costimulatory	O
molecules	O
such	O
as	O
CD40	B-GP
,	O
CD30	B-GP
,	O
Herpes	B-GP
virus	I-GP
entry	I-GP
mediator	I-GP
(	O
HVEM	B-GP
),	O
4	B-GP
-	I-GP
1BB	I-GP
,	O
OX40	B-GP
,	O
CD27	B-GP
,	O
DR3	B-GP
,	O
and	O
glucocorticoid	B-GP
-	I-GP
induced	I-GP
TNFR	I-GP
-	I-GP
related	I-GP
protein	I-GP
(	O
GITR	B-GP
)	O
18	O
.	O

In	O
a	O
previous	O
report	O
,	O
mice	B-OG
with	O
a	O
targeted	O
deletion	O
of	O
the	O
Tnfrsf21	B-GP
gene	O
(	O
encoding	O
DR6	B-GP
)	O
exhibited	O
hyper	O
production	O
of	O
immunoglobulins	B-GP
after	O
antigen	O
stimulation19	O
,	O
and	O
DR6	B-GP
deficiency	O
in	O
peripheral	O
T	O
cells	O
enhances	O
the	O
production	O
of	O
cytokines	B-GP
for	O
facilitating	O
B	O
cell	O
activation	O
and	O
differentiation	O
,	O
as	O
well	O
as	O
the	O
antigen	O
-	O
dependent	O
activation	O
of	O
transcriptional	B-GP
factors	I-GP
such	O
as	O
the	O
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cells	I-GP
(	O
NFAT	B-GP
)	O
or	O
nuclear	B-GP
factor	I-GP
-	I-GP
kappa	I-GP
B	I-GP
(	O
NFÎºB	B-GP
)	O
20	O
.	O

DR6	B-GP
is	O
associated	O
with	O
the	O
regulations	O
on	O
T	O
cell	O
function	O
in	O
several	O
immunological	B-DS
diseases	I-DS
,	O
including	O
experimental	B-DS
autoimmune	I-DS
encephalomyelitis	I-DS
(	O
EAE	B-DS
),	O
asthma	B-DS
,	O
and	O
acute	B-DS
graft	I-DS
versus	I-DS
host	I-DS
disease	I-DS
in	O
animal	B-OG
models212223	O
.	O

DR6	B-GP
is	O
weakly	O
expressed	O
on	O
resting	O
peripheral	O
CD4	B-GP
+	O
T	O
cells	O
and	O
upregulated	O
in	O
response	O
to	O
TCR	B-GP
stimulation24	O
.	O

Importantly	O
,	O
the	O
association	O
of	O
TNFRSF21	B-GP
gene	O
induction	O
with	O
disease	O
progression	O
was	O
reported	O
in	O
SLE	B-DS
patients2526	O
.	O

Although	O
the	O
molecular	O
mechanism	O
of	O
action	O
,	O
including	O
its	O
immunological	O
ligand	O
,	O
is	O
unknown	O
,	O
DR6	B-GP
may	O
have	O
a	O
critical	O
role	O
in	O
autoimmune	B-DS
disease	I-DS
progression	O
.	O

Syndecan	B-GP
-	I-GP
1	I-GP
is	O
a	O
glycosylated	B-GP
type	I-GP
-	I-GP
I	I-GP
transmembrane	I-GP
protein	I-GP
.	O

In	O
in	O
vitro	O
experiments	O
,	O
syndecan	B-GP
-	I-GP
1	I-GP
binds	O
to	O
various	O
soluble	O
proteins	O
via	O
its	O
attached	O
oligosaccharide	O
chains	O
.	O

Therefore	O
,	O
syndecan	B-GP
-	I-GP
1	I-GP
may	O
act	O
as	O
a	O
scaffold	O
for	O
soluble	O
factors	O
,	O
inducing	O
the	O
accumulation	O
of	O
inflammatory	O
cells	O
in	O
localized	O
inflammation27	O
.	O

By	O
contrast	O
,	O
several	O
studies	O
suggest	O
that	O
syndecan	B-GP
-	I-GP
1	I-GP
has	O
a	O
suppressive	O
function	O
on	O
the	O
progression	O
of	O
immunological	B-DS
diseases	I-DS
.	O

Similar	O
to	O
DR6	B-GP
deficiency	O
,	O
syndecan	B-GP
-	I-GP
1	I-GP
deficiency	O
increases	O
the	O
severity	O
of	O
disease	O
,	O
lymphocyte	O
activation	O
,	O
as	O
well	O
as	O
production	O
of	O
antigen	O
-	O
specific	O
plasma	O
cells	O
and	O
immunoglobulins	B-GP
in	O
the	O
peripheral	O
lymphoid	O
organs	O
of	O
EAE	B-DS
,	O
immune	O
complex	O
-	O
mediated	O
murine	O
nephritis	B-DS
,	O
and	O
allergic	O
lung	B-DS
inflammation	I-DS
animal	B-OG
models282930	O
.	O

These	O
findings	O
suggest	O
the	O
presence	O
of	O
an	O
undefined	O
regulatory	O
function	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
in	O
peripheral	O
lymphocyte	O
activation27	O
.	O

The	O
amount	O
of	O
syndecan	O
-	O
1shed	O
into	O
the	O
peripheral	O
blood	O
has	O
been	O
shown	O
to	O
correlate	O
with	O
disease	O
severity	O
in	O
SLE	B-DS
patients3132	O
.	O

Although	O
most	O
CD19	B-GP
+	O
B	O
cells	O
do	O
not	O
express	O
syndecan	B-GP
-	I-GP
1	I-GP
,	O
CD19	B-GP
+	O
autoreactive	O
pre	O
-	O
plasma	O
cells	O
express	O
syndecan	B-GP
-	I-GP
1	I-GP
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
and	O
SLE	B-DS
patients3233	O
.	O

These	O
findings	O
suggest	O
that	O
syndecan	B-GP
-	I-GP
1	I-GP
is	O
also	O
engaged	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	B-DS
diseases	I-DS
.	O

However	O
,	O
the	O
details	O
of	O
the	O
suppressive	O
function	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
,	O
particularly	O
on	O
pathogenic	O
lymphocyte	O
maturation	O
and	O
activation	O
,	O
are	O
unclear27	O
.	O

Here	O
we	O
show	O
an	O
increase	O
in	O
DR6	B-GP
expression	O
on	O
Tfh	O
cells	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

Importantly	O
,	O
we	O
identify	O
syndecan	B-GP
-	I-GP
1	I-GP
as	O
a	O
binding	O
partner	O
for	O
DR6	B-GP
,	O
and	O
we	O
clarify	O
whether	O
and	O
how	O
this	O
dysregulated	O
DR6	B-GP
/	O
syndecan	B-GP
-	I-GP
1	I-GP
interaction	O
leads	O
to	O
autoimmunity	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

Results	O

Induction	O
of	O
DR6	B-GP
+	O
CD4	B-GP
+	O
T	O
cells	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG

Recent	O
independent	O
studies	O
have	O
reported	O
that	O
upregulation	O
of	O
the	O
TNFRSF21	B-GP
gene	O
is	O
associated	O
with	O
disease	O
prognosis	O
by	O
genome	O
-	O
wide	O
gene	O
expression	O
analysis	O
using	O
peripheral	O
mononuclear	O
cells	O
obtained	O
from	O
SLE	B-DS
patients2526	O
.	O

To	O
explore	O
the	O
details	O
of	O
the	O
association	O
between	O
DR6	B-GP
and	O
disease	O
,	O
we	O
generated	O
a	O
rat	B-OG
anti	O
-	O
DR6	B-GP
monoclonal	O
antibody	O
(	O
clone	O
25	O
-	O
1	O
,	O
IgG1	B-GP
).	O

The	O
specificity	O
of	O
25	O
-	O
1	O
antibody	O
(	O
25	O
-	O
1	O
Ab	O
)	O
is	O
demonstrated	O
in	O
Supplementary	O
Fig	O
.	O
1	O
.	O

Briefly	O
,	O
25	O
-	O
1	O
Ab	O
bound	O
DR6	B-GP
stably	O
expressed	O
on	O
L929	O
cells	O
(	O
L929	O
-	O
mDR6	O
)	O
(	O
Supplementary	O
Fig	O
.	O
1a	O
).	O

25	O
-	O
1	O
Abs	O
specifically	O
bound	O
to	O
DR6	B-GP
,	O
but	O
not	O
to	O
other	O
TNFRSF	B-GP
molecules	O
that	O
were	O
expressed	O
on	O
the	O
cell	O
surface	O
(	O
Supplementary	O
Fig	O
.	O
1b	O
).	O

25	O
-	O
1	O
Abs	O
could	O
also	O
bind	O
to	O
endogenous	O
DR6	B-GP
,	O
expressed	O
by	O
murine	O
T	O
cell	O
hybridoma	O
(	O
DO11	O
.	O
10	O
-	O
T	O
)	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
1c	O
,	O
left	O
panel	O
),	O
and	O
this	O
reactivity	O
was	O
lost	O
after	O
Tnfrsf21	B-GP
gene	O
-	O
specific	O
knockout	O
based	O
on	O
the	O
CRISPR	O
-	O
Cas9	B-GP
system	O
(	O
G510	O
-	O
8	O
-	O
7	O
or	O
-	O
10	O
-	O
4	O
)	O
(	O
Supplementary	O
Fig	O
.	O
1c	O
,	O
middle	O
and	O
right	O
panels	O
),	O
indicating	O
that	O
25	O
-	O
1	O
Abs	O
react	O
with	O
endogenous	O
DR6	B-GP
but	O
not	O
the	O
other	O
proteins	O
expressed	O
on	O
the	O
cell	O
(	O
Supplementary	O
Fig	O
.	O
1c	O
,	O
d	O
).	O

We	O
used	O
25	O
-	O
1	O
Abs	O
to	O
detect	O
mouse	B-OG
DR6	B-GP
expression	O
hereafter	O
.	O

Splenocytes	O
were	O
obtained	O
from	O
anti	O
-	O
DNA	O
Ab	O
negative	O
(	O
10	O
weeks	O
of	O
age	O
)	O
and	O
positive	O
(	O
24	O
weeks	O
of	O
age	O
)	O
female	O
New	O
Zealand	O
Black	O
Ã	O
New	O
Zealand	O
White	O
F1	O
(	O
BWF1	O
)	O
mice	B-OG
and	O
age	O
-	O
and	O
sex	O
matched	O
healthy	O
B6	B-OG
mice	I-OG
.	O

Interestingly	O
,	O
we	O
identified	O
the	O
induction	O
of	O
DR6	B-GP
-	O
expressing	O
cells	O
in	O
splenocytes	O
obtained	O
from	O
BWF1	O
but	O
not	O
B6	B-OG
mice	I-OG
.	O

The	O
majority	O
of	O
DR6	B-GP
+	O
cells	O
were	O
CD3	B-GP
+	O
T	O
cells	O
in	O
all	O
mice	B-OG
that	O
were	O
tested	O
.	O

DR6	B-GP
+	O
cells	O
were	O
increased	O
in	O
an	O
age	O
-	O
dependent	O
fashion	O
in	O
BWF1	B-OG
mice	I-OG
(	O
Fig	O
.	O
1a	O
).	O

Interestingly	O
,	O
a	O
unique	O
CD4	B-GP
+	O
subset	O
expressing	O
DR6	B-GP
was	O
observed	O
in	O
autoreactive	O
Ab	O
positive	O
lupus	B-DS
-	O
prone	O
BWF1	O
(	O
aged	O
24	O
weeks	O
)	O
but	O
not	O
in	O
autoreactive	O
Ab	O
negative	O
B6	B-OG
mice	I-OG
(	O
aged	O
10	O
and	O
24	O
weeks	O
;	O
Fig	O
.	O
1b	O
,	O
c	O
).	O

Most	O
of	O
the	O
CD8	B-GP
+	O
T	O
cells	O
also	O
expressed	O
DR6	B-GP
in	O
BWF1	B-OG
mice	I-OG
(	O
Fig	O
.	O
1d	O
,	O
e	O
).	O

While	O
CD4	B-GP
+	O
T	O
cells	O
of	O
BWF1	B-OG
mice	I-OG
markedly	O
expanded	O
with	O
disease	O
progression	O
,	O
CD8	B-GP
+	O
T	O
cells	O
were	O
minimally	O
expanded	O
in	O
the	O
mice	B-OG
(	O
Fig	O
.	O
1f	O
).	O

Therefore	O
,	O
we	O
decided	O
to	O
further	O
define	O
which	O
subpopulation	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressed	O
DR6	B-GP
.	O

DR6	B-GP
expression	O
on	O
Tfh	O
cells	O
of	O
lupus	B-DS
-	O
prone	O
mice	B-OG

Follicular	O
helper	O
T	O
(	O
Tfh	O
)	O
cells	O
expand	O
and	O
promote	O
disease	O
progression	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

Therefore	O
,	O
we	O
asked	O
whether	O
DR6	B-GP
expression	O
was	O
associated	O
with	O
Tfh	O
cells	O
in	O
lupus	B-DS
-	O
prone	O
BWF1	B-OG
mice	I-OG
.	O

Thus	O
,	O
we	O
characterized	O
Bcl6	B-GP
expression	O
of	O
DR6	B-GP
+	O
CD4	B-GP
+	O
cells	O
by	O
intracellular	O
staining	O
since	O
Bcl6	B-GP
is	O
a	O
key	O
transcriptional	O
factor	O
for	O
Tfh	O
cells	O
(	O
Fig	O
.	O
2a	O
).	O

Interestingly	O
,	O
we	O
detected	O
anti	O
-	O
Bcl6	B-GP
antibody	O
specific	O
signal	O
in	O
DR6	B-GP
+	O
CD4	B-GP
+	O
splenocytes	O
isolated	O
from	O
24	O
-	O
week	O
-	O
old	O
BWF1	B-OG
mice	I-OG
(	O
Fig	O
.	O
2a	O
).	O

We	O
also	O
analysed	O
DR6	B-GP
expression	O
among	O
Tfh	O
cells	O
that	O
expanded	O
in	O
lupus	B-DS
-	O
prone	O
BWF1	B-OG
mice	I-OG
.	O

The	O
expanded	O
Tfh	O
cells	O
were	O
detected	O
by	O
their	O
expression	O
of	O
CXCR5	B-GP
and	O
PD1	B-GP
among	O
7AAD	O
â	O
(	O
live	O
)	O
CD19	B-GP
â	O
CD4	B-GP
+	O
splenocytes	O
of	O
24	O
-	O
week	O
-	O
old	O
female	O
BWF1	B-OG
mice	I-OG
(	O
Fig	O
.	O
2b	O
,	O
upper	O
panel	O
),	O
but	O
not	O
in	O
age	O
-	O
and	O
sex	O
matched	O
B6	B-OG
mice	I-OG
(	O
Fig	O
.	O
2b	O
,	O
lower	O
panel	O
).	O

By	O
their	O
CXCR5	B-GP
and	O
PD1	B-GP
expression	O
levels	O
,	O
the	O
expanded	O
Tfh	O
cells	O
could	O
also	O
be	O
separated	O
into	O
three	O
populations	O
;	O
CXCR5high	O
/	O
PD1high	O
(	O
mature	O
Tfh	O
cells	O
)	O
and	O
CXCR5int	O
/	O
PD1int	O
(	O
pre	O
-	O
Tfh	O
cells	O
)	O
or	O
CXCR5	B-GP
â/	O
PD1	B-GP
â	O
(	O
non	O
-	O
Tfh	O
cells	O
).	O

To	O
determine	O
Tnfrsf21	B-GP
gene	O
expression	O
of	O
these	O
three	O
Tfh	O
cell	O
populations	O
,	O
we	O
sorted	O
these	O
cells	O
from	O
splenocytes	O
of	O
24	O
-	O
week	O
-	O
old	O
BWF1	B-OG
mice	I-OG
.	O

We	O
then	O
detected	O
expression	O
of	O
the	O
Tnfrsf21	B-GP
gene	O
in	O
these	O
isolated	O
cells	O
by	O
quantitative	O
PCR	O
(	O
Fig	O
.	O
2c	O
).	O
Tnfrsf21	B-GP
mRNA	O
expression	O
was	O
detected	O
in	O
each	O
cell	O
population	O
isolated	O
from	O
BWF1	B-OG
mice	I-OG
.	O

The	O
expression	O
was	O
highest	O
in	O
Tfh	O
cells	O
;	O
intermediate	O
in	O
pre	O
-	O
Tfh	O
and	O
low	O
in	O
non	O
-	O
Tfh	O
cells	O
.	O

We	O
also	O
analysed	O
the	O
DR6	B-GP
protein	O
expression	O
of	O
these	O
Tfh	O
cell	O
populations	O
.	O

In	O
flow	O
cytometrical	O
assays	O
,	O
DR6	B-GP
expressing	O
cells	O
were	O
observed	O
in	O
each	O
Tfh	O
cell	O
population	O
.	O

The	O
frequency	O
of	O
DR6	B-GP
+	O
cells	O
was	O
highest	O
in	O
Tfh	O
cells	O
,	O
intermediate	O
in	O
pre	O
-	O
Tfh	O
cells	O
and	O
rare	O
in	O
non	O
-	O
Tfh	O
cells	O
(	O
Fig	O
.	O
2d	O
,	O
left	O
panels	O
).	O

The	O
DR6	B-GP
expression	O
on	O
Tfh	O
cells	O
correlated	O
with	O
the	O
expression	O
of	O
another	O
Tfh	O
-	O
associated	O
surface	O
molecule	O
,	O
CXCR4	B-GP
,	O
by	O
the	O
cells	O
(	O
Fig	O
.	O
2d	O
,	O
middle	O
and	O
right	O
panels	O
).	O

These	O
findings	O
indicated	O
that	O
DR6	B-GP
is	O
expressed	O
on	O
Tfh	O
cells	O
that	O
expand	O
in	O
lupus	B-DS
-	O
prone	O
BWF1	B-OG
mice	I-OG
.	O

Identification	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
as	O
a	O
ligand	O
for	O
DR6	B-GP

To	O
understand	O
in	O
detail	O
the	O
function	O
of	O
DR6	B-GP
in	O
immunological	O
events	O
,	O
specific	O
ligand	O
(	O
s	O
)	O
for	O
DR6	B-GP
required	O
discovery	O
.	O

To	O
identify	O
the	O
DR6	B-GP
ligand	O
(	O
s	O
),	O
we	O
generated	O
a	O
soluble	O
fusion	O
protein	O
consisting	O
of	O
an	O
extracellular	O
domain	O
of	O
murine	O
DR6	B-GP
and	O
the	O
Fc	O
portion	O
of	O
human	B-OG
IgG	B-GP
(	O
DR6	B-GP
-	O
Fc	O
).	O

We	O
observed	O
a	O
small	O
portion	O
of	O
the	O
cells	O
bound	O
to	O
DR6	B-GP
-	O
Fc	O
in	O
total	O
splenocytes	O
obtained	O
from	O
B6	B-OG
mice	I-OG
(	O
Fig	O
.	O
3a	O
,	O
red	O
box	O
in	O
left	O
panel	O
).	O

Most	O
of	O
the	O
cells	O
bound	O
to	O
DR6	B-GP
-	O
Fc	O
were	O
detected	O
in	O
the	O
lymphocytes	O
gate	O
on	O
a	O
SSC	O
versus	O
FSC	O
dot	O
plot	O
(	O
Fig	O
.	O
3a	O
,	O
right	O
panels	O
).	O

We	O
also	O
stained	O
total	O
splenocytes	O
with	O
DR6	B-GP
-	O
Fc	O
and	O
a	O
specific	O
antibody	O
against	O
the	O
indicated	O
cell	O
type	O
marker	O
.	O

The	O
cells	O
bound	O
to	O
DR6	B-GP
-	O
Fc	O
were	O
detected	O
with	O
an	O
antibody	O
against	O
a	O
surface	O
marker	O
for	O
B	O
cells	O
,	O
B220	B-GP
,	O
but	O
not	O
for	O
other	O
cell	O
populations	O
tested	O
(	O
Fig	O
.	O
3b	O
,	O
red	O
coloured	O
box	O
).	O

The	O
murine	O
A20	O
B	O
cell	O
line	O
,	O
but	O
not	O
DO11	O
.	O
10	O
-	O
T	O
cell	O
hybridoma	O
,	O
preferentially	O
bound	O
to	O
DR6	B-GP
-	O
Fc	O
(	O
Fig	O
.	O
3c	O
).	O

Thus	O
,	O
we	O
constructed	O
expression	O
plasmids	O
of	O
full	O
-	O
length	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
library	O
obtained	O
from	O
DR6	B-GP
-	O
Fc	O
-	O
positive	O
A20	O
cells	O
and	O
retrovirally	O
transfected	O
the	O
plasmids	O
into	O
DR6	B-GP
-	O
Fc	O
-	O
negative	O
DO11	O
.	O
10	O
-	O
T	O
cells	O
.	O

Then	O
,	O
we	O
isolated	O
the	O
transfectants	O
bound	O
to	O
DR6	B-GP
-	O
Fc	O
during	O
four	O
rounds	O
of	O
sorting	O
and	O
culturing	O
expansions	O
(	O
Fig	O
.	O
3d	O
).	O

After	O
the	O
fifth	O
round	O
,	O
we	O
recovered	O
a	O
single	O
library	O
-	O
specific	O
cDNA	O
fragment	O
(	O
approximately	O
3	O
,	O
000	O
bp	O
in	O
length	O
)	O
inserted	O
in	O
genomic	O
DNA	O
of	O
the	O
isolated	O
transfectants	O
(	O
Fig	O
.	O
3e	O
).	O

Surprisingly	O
,	O
the	O
fragment	O
encoded	O
the	O
sequence	O
for	O
the	O
full	O
-	O
length	O
mRNA	O
of	O
murine	O
Syndecan	B-GP
-	I-GP
1	I-GP
(	O
Sdc1	B-GP
).	O

The	O
binding	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
to	O
DR6	B-GP
was	O
confirmed	O
by	O
human	B-OG
and	O
mouse	B-OG
syndecan	B-GP
-	I-GP
1	I-GP
ectopically	O
expressed	O
on	O
DO11	O
.	O
10T	O
cells	O
binding	O
to	O
the	O
DR6	B-GP
ectodomain	O
(	O
Fig	O
.	O
3f	O
).	O

We	O
then	O
analysed	O
the	O
molecular	O
specificity	O
of	O
the	O
interaction	O
between	O
syndecan	B-GP
-	I-GP
1	I-GP
and	O
DR6	B-GP
(	O
Supplementary	O
Fig	O
.	O
2	O
).	O

We	O
retrovirally	O
transfected	O
plasmids	O
expressing	O
non	O
-	O
specific	O
(	O
shLuc	O
)	O
or	O
Syndecan	B-GP
-	I-GP
1	I-GP
-	O
specific	O
(	O
shmSdc1	O
)	O
shRNAs	O
into	O
A20	O
cells	O
.	O

Using	O
flow	O
cytometry	O
,	O
we	O
confirmed	O
the	O
effective	O
knockdown	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
protein	O
expression	O
mediated	O
by	O
shmSdc1	O
,	O
but	O
not	O
shLuc	O
,	O
in	O
A20	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
2a	O
).	O

We	O
also	O
confirmed	O
that	O
shmSdc1	O
treatment	O
did	O
not	O
affect	O
B220	B-GP
expression	O
of	O
the	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
2b	O
).	O

In	O
a	O
further	O
flow	O
cytometrical	O
assay	O
using	O
DR6	B-GP
-	O
Fc	O
,	O
shmSdc1	O
but	O
not	O
shLuc	O
treatment	O
dramatically	O
reduced	O
the	O
binding	O
of	O
DR6	B-GP
-	O
Fc	O
to	O
A20	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
2c	O
).	O

In	O
the	O
same	O
assay	O
using	O
the	O
indicated	O
recombinant	O
Fc	O
proteins	O
,	O
syndecan	B-GP
-	I-GP
1	I-GP
expressed	O
on	O
A20	O
cells	O
preferentially	O
bound	O
to	O
DR6	B-GP
-	O
Fc	O
compared	O
with	O
Fc	O
proteins	O
obtained	O
from	O
the	O
other	O
TNFRSF	B-GP
molecules	O
(	O
Supplementary	O
Fig	O
.	O
2d	O
).	O

This	O
syndecan	B-GP
-	I-GP
1	I-GP
specific	O
interaction	O
of	O
DR6	B-GP
was	O
consistent	O
with	O
the	O
observation	O
that	O
the	O
genome	O
-	O
wide	O
screening	O
identified	O
only	O
syndecan	B-GP
-	I-GP
1	I-GP
as	O
a	O
binding	O
molecule	O
for	O
the	O
DR6	B-GP
-	O
ectodomain	O
(	O
Fig	O
.	O
3e	O
).	O

We	O
also	O
analysed	O
binding	O
specificity	O
within	O
the	O
molecular	O
structures	O
of	O
DR6	B-GP
(	O
Fig	O
.	O
3g	O
).	O

Four	O
cysteine	O
-	O
rich	O
domains	O
(	O
CRDs	O
)	O
are	O
conserved	O
in	O
the	O
extracellular	O
region	O
of	O
DR6	B-GP
and	O
are	O
involved	O
in	O
ligand	O
binding17	O
.	O

We	O
generated	O
recombinant	O
Fc	O
proteins	O
fused	O
with	O
DR6	B-GP
-	O
extracellular	O
domain	O
lacking	O
CRD1	O
(	O
ÎCRD1	O
),	O
CRD2	O
(	O
ÎCRD2	O
),	O
CRD3	O
(	O
ÎCRD3	O
)	O
or	O
CRD4	O
(	O
ÎCRD4	O
).	O

Then	O
,	O
these	O
recombinant	O
proteins	O
were	O
pulled	O
down	O
with	O
syndecan	B-GP
-	I-GP
1	I-GP
endogenously	O
expressed	O
on	O
A20	O
cells	O
.	O

The	O
precipitated	O
syndecan	B-GP
-	I-GP
1	I-GP
was	O
detected	O
with	O
an	O
anti	O
-	O
syndecan	B-GP
-	I-GP
1	I-GP
Ab	O
.	O

Among	O
the	O
tested	O
Fc	O
proteins	O
,	O
the	O
mutants	O
lacking	O
CRD2	O
or	O
CRD3	O
were	O
not	O
capable	O
of	O
precipitating	O
syndecan	B-GP
-	I-GP
1	I-GP
.	O

The	O
observed	O
dependence	O
of	O
the	O
interaction	O
on	O
CRD2	O
and	O
-	O
3	O
is	O
in	O
agreement	O
with	O
the	O
previous	O
observations	O
that	O
both	O
CRD2	O
and	O
-	O
3	O
of	O
DR6	B-GP
are	O
positively	O
charged	O
for	O
its	O
ligand	O
binding34	O
.	O

We	O
further	O
demonstrated	O
a	O
molecular	O
function	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
/	O
DR6	B-GP
interaction	O
in	O
T	O
cell	O
activation	O
(	O
Fig	O
.	O
3h	O
).	O

DO11	O
.	O
10	O
-	O
T	O
cells	O
were	O
electroporated	O
with	O
the	O
indicated	O
transcription	B-GP
factor	I-GP
-	O
dependent	O
reporter	O
plasmids	O
.	O

Then	O
,	O
the	O
cells	O
were	O
stimulated	O
with	O
or	O
without	O
recombinant	O
syndecan	B-GP
-	I-GP
1	I-GP
(	O
recSdc1	O
)	O
under	O
activation	O
of	O
TCR	B-GP
signalling	O
mediated	O
by	O
anti	O
-	O
CD3	B-GP
Ab	O
.	O

CD3	B-GP
cross	O
-	O
linking	O
dramatically	O
activated	O
NFAT	B-GP
in	O
the	O
cells	O
(	O
Fig	O
.	O
3h	O
,	O
gray	O
in	O
left	O
columns	O
).	O

Interestingly	O
,	O
the	O
recSdc1	O
stimulation	O
suppressed	O
NFAT	B-GP
activation	O
(	O
Fig	O
.	O
3h	O
,	O
red	O
versus	O
gray	O
in	O
left	O
columns	O
).	O

The	O
suppressive	O
effect	O
of	O
recSdc1	O
was	O
also	O
observed	O
in	O
the	O
reporter	O
assay	O
detecting	O
NFÎºB	B-GP
activation	O
(	O
Fig	O
.	O
3h	O
,	O
right	O
columns	O
).	O

We	O
also	O
demonstrated	O
the	O
suppressive	O
function	O
of	O
recSdc1	O
by	O
assessing	O
IL	B-GP
-	I-GP
2	I-GP
production	O
,	O
which	O
depends	O
on	O
NFAT	B-GP
and	O
NFÎºB	B-GP
activation	O
(	O
Fig	O
.	O
3i	O
).	O

Parental	O
DO11	O
.	O
10T	O
cells	O
or	O
their	O
DR6	B-GP
deficient	O
clones	O
(	O
Supplementary	O
Fig	O
.	O
1c	O
,	O
d	O
)	O
were	O
stimulated	O
with	O
the	O
indicated	O
combinations	O
of	O
anti	O
-	O
CD3	B-GP
Ab	O
and	O
recSdc1	O
.	O

Parental	O
DO11	O
.	O
10T	O
cells	O
produced	O
IL	B-GP
-	I-GP
2	I-GP
in	O
response	O
to	O
anti	O
-	O
CD3	B-GP
Ab	O
,	O
whereas	O
the	O
cells	O
produced	O
decreased	O
IL	B-GP
-	I-GP
2	I-GP
in	O
the	O
presence	O
of	O
recSdc1	O
(	O
Fig	O
.	O
3i	O
,	O
opened	O
compared	O
with	O
closed	O
column	O
in	O
black	O
coloured	O
columns	O
).	O

Interestingly	O
,	O
DR6	B-GP
deficient	O
DO11	O
.	O
10T	O
cell	O
clones	O
produced	O
IL	B-GP
-	I-GP
2	I-GP
in	O
the	O
presence	O
or	O
absence	O
of	O
recSdc1	O
,	O
indicating	O
that	O
the	O
suppressive	O
effect	O
of	O
recSdc1	O
depends	O
on	O
DR6	B-GP
expression	O
by	O
the	O
cells	O
(	O
Fig	O
.	O
3i	O
,	O
opened	O
compared	O
with	O
closed	O
in	O
red	O
or	O
blue	O
columns	O
).	O

These	O
findings	O
demonstrate	O
that	O
syndecan	B-GP
-	I-GP
1	I-GP
is	O
a	O
specific	O
binding	O
partner	O
for	O
DR6	B-GP
and	O
the	O
interaction	O
negatively	O
regulates	O
NFAT	B-GP
and	O
NFÎºB	B-GP
activation	O
during	O
TCR	B-GP
activation	O
.	O

Syndecan	B-GP
-	I-GP
1	I-GP
on	O
autoreactive	O
germinal	O
centre	O
B	O
cells	O

We	O
next	O
considered	O
whether	O
syndecan	B-GP
-	I-GP
1	I-GP
was	O
associated	O
with	O
a	O
specific	O
B	O
cell	O
population	O
,	O
germinal	O
centre	O
(	O
GC	O
)	O
B	O
cells	O
,	O
because	O
the	O
GC	O
B	O
cell	O
provides	O
critical	O
signals	O
for	O
complete	O
maturation	O
and	O
expansion	O
of	O
Tfh	O
cells	O
in	O
lupus	B-DS
-	O
prone	O
mice9103536	O
.	O

We	O
isolated	O
spleens	O
from	O
non	O
-	O
immunized	O
24	O
-	O
week	O
-	O
old	O
female	O
BWF1	O
and	O
NZB	B-OG
mice	I-OG
.	O

On	O
the	O
splenic	O
cryosections	O
of	O
BWF1	B-OG
mice	I-OG
,	O
anti	O
-	O
GL7	B-GP
Ab	O
stained	O
the	O
GC	O
cells	O
,	O
which	O
were	O
markedly	O
expanded	O
on	O
the	O
border	O
between	O
the	O
T	O
-	O
and	O
B	O
-	O
cell	O
zones	O
(	O
Fig	O
.	O
4a	O
,	O
cyan	O
in	O
left	O
panel	O
).	O

Interestingly	O
,	O
the	O
GL7	B-GP
+	O
GC	O
cells	O
were	O
also	O
stained	O
with	O
anti	O
-	O
syndecan	B-GP
-	I-GP
1	I-GP
Ab	O
(	O
Fig	O
.	O
4a	O
,	O
green	O
in	O
right	O
panel	O
).	O

In	O
another	O
lupus	B-DS
-	O
prone	O
mouse	B-OG
strain	O
,	O
NZB	B-OG
mice	I-OG
,	O
the	O
GC	O
cells	O
(	O
Fig	O
.	O
4b	O
,	O
cyan	O
)	O
also	O
expressed	O
syndecan	B-GP
-	I-GP
1	I-GP
(	O
Fig	O
.	O
4b	O
,	O
green	O
).	O

The	O
same	O
results	O
were	O
obtained	O
from	O
other	O
sections	O
(	O
Supplementary	O
Fig	O
.	O
3	O
).	O

Comparing	O
the	O
observations	O
obtained	O
from	O
BWF1	O
(	O
Fig	O
.	O
4a	O
)	O
with	O
NZB	B-OG
mice	I-OG
(	O
Fig	O
.	O
4b	O
),	O
we	O
found	O
some	O
differences	O
;	O
(	O
1	O
)	O
the	O
level	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
expression	O
on	O
GC	O
cells	O
was	O
higher	O
in	O
NZB	O
than	O
BWF1	B-OG
mice	I-OG
,	O
and	O
(	O
2	O
)	O
the	O
size	O
of	O
expanded	O
GC	O
cells	O
was	O
smaller	O
in	O
NZB	O
than	O
BWF1	B-OG
mice	I-OG
.	O

To	O
confirm	O
the	O
former	O
,	O
we	O
assessed	O
the	O
expression	O
level	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
on	O
GL7	B-GP
+	O
CD19	B-GP
+	O
GC	O
B	O
cells	O
using	O
flow	O
cytometry	O
.	O

As	O
expected	O
,	O
the	O
level	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
expression	O
on	O
GL7	B-GP
+	O
CD19	B-GP
+	O
GC	O
B	O
cells	O
of	O
NZB	B-OG
mice	I-OG
was	O
higher	O
than	O
that	O
of	O
BWF1	B-OG
mice	I-OG
(	O
Fig	O
.	O
4c	O
,	O
upper	O
panel	O
).	O

The	O
levels	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
expression	O
of	O
GL7	B-GP
â	O
CD19	B-GP
+	O
non	O
-	O
GC	O
B	O
cells	O
were	O
low	O
and	O
comparable	O
between	O
lupus	B-DS
-	O
prone	O
and	O
healthy	O
B6	B-OG
mice	I-OG
(	O
Fig	O
.	O
4c	O
,	O
upper	O
panel	O
),	O
although	O
CD19	B-GP
expression	O
level	O
was	O
comparable	O
among	O
these	O
cells	O
(	O
Fig	O
.	O
4c	O
,	O
lower	O
panel	O
).	O

To	O
confirm	O
the	O
latter	O
,	O
we	O
calculated	O
the	O
numbers	O
and	O
percentages	O
of	O
GC	O
B	O
cells	O
in	O
these	O
mice	B-OG
strains	O
.	O

While	O
GL7	B-GP
+	O
CD19	B-GP
+	O
GC	O
B	O
cells	O
hardly	O
developed	O
in	O
healthy	O
non	O
-	O
immunized	O
B6	B-OG
mice	I-OG
,	O
the	O
cells	O
expanded	O
in	O
lupus	B-DS
-	O
prone	O
NZB	O
and	O
BWF1	B-OG
mice	I-OG
(	O
Fig	O
.	O
4d	O
,	O
upper	O
panel	O
).	O

The	O
number	O
of	O
the	O
GC	O
B	O
cells	O
was	O
significantly	O
lower	O
in	O
the	O
spleen	O
of	O
NZB	B-OG
mice	I-OG
compared	O
with	O
BWF1	B-OG
mice	I-OG
(	O
Fig	O
.	O
4d	O
,	O
upper	O
panel	O
).	O

The	O
percentage	O
of	O
GC	O
B	O
cells	O
was	O
also	O
comparable	O
among	O
these	O
lupus	B-DS
-	O
prone	O
mice	B-OG
strains	O
(	O
Fig	O
.	O
4d	O
,	O
lower	O
panel	O
).	O

Therefore	O
,	O
lupus	B-DS
-	O
specific	O
expansion	O
of	O
GC	O
B	O
cell	O
should	O
be	O
restricted	O
in	O
NZB	O
,	O
although	O
the	O
GC	O
B	O
cells	O
developed	O
in	O
both	O
NZB	O
and	O
BWF1	B-OG
mice	I-OG
.	O

Further	O
analysis	O
also	O
showed	O
the	O
NZB	O
specific	O
restriction	O
of	O
the	O
expansion	O
of	O
both	O
pre	O
-	O
Tfh	O
(	O
Fig	O
.	O
4e	O
,	O
left	O
panels	O
)	O
and	O
Tfh	O
cells	O
(	O
Fig	O
.	O
4e	O
,	O
right	O
panels	O
).	O

Therefore	O
,	O
we	O
wondered	O
whether	O
syndecan	B-GP
-	I-GP
1	I-GP
was	O
associated	O
with	O
the	O
regulation	O
of	O
Tfh	O
cells	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

To	O
answer	O
this	O
question	O
,	O
we	O
isolated	O
DR6	B-GP
-	O
expressing	O
Tfh	O
cells	O
from	O
BWF1	B-OG
mice	I-OG
and	O
stimulated	O
the	O
cells	O
with	O
recSdc1	O
in	O
conjunction	O
with	O
TCR	B-GP
activation	O
in	O
vitro	O
.	O

Surprisingly	O
,	O
recSdc1	O
stimulation	O
(	O
at	O
30	O
nM	O
)	O
suppressed	O
Il	B-GP
-	I-GP
21	I-GP
production	O
by	O
the	O
Tfh	O
cells	O
during	O
activation	O
(	O
Fig	O
.	O
4f	O
).	O

The	O
recSdc1	O
-	O
mediated	O
suppressive	O
effect	O
was	O
not	O
due	O
to	O
a	O
cytotoxic	O
effect	O
on	O
the	O
Tfh	O
cells	O
because	O
30	O
nM	O
recSdc1	O
did	O
not	O
stimulate	O
cell	O
death	O
induction	O
in	O
DO11	O
.	O
10T	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
4	O
)	O
or	O
the	O
Tfh	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
5	O
).	O

These	O
findings	O
indicate	O
that	O
syndecan	B-GP
-	I-GP
1	I-GP
was	O
expressed	O
on	O
GC	O
B	O
cells	O
of	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

Suppression	O
of	O
DR6	B-GP
+	O
Tfh	O
cells	O
delays	O
disease	O
progression	O

We	O
found	O
that	O
25	O
-	O
1	O
Ab	O
is	O
capable	O
of	O
DR6	B-GP
cross	O
-	O
linking	O
in	O
in	O
vitro	O
experiments	O
(	O
Supplementary	O
Fig	O
.	O
6	O
,	O
the	O
details	O
are	O
described	O
in	O
the	O
legend	O
).	O

In	O
addition	O
,	O
25	O
-	O
1	O
Ab	O
suppressed	O
Il	B-GP
-	I-GP
21	I-GP
production	O
by	O
DR6	B-GP
-	O
expressing	O
Tfh	O
cells	O
isolated	O
from	O
BWF1	B-OG
mice	I-OG
(	O
Fig	O
.	O
5a	O
).	O

This	O
effect	O
was	O
not	O
due	O
to	O
cytotoxicity	O
because	O
25	O
-	O
1	O
Ab	O
did	O
not	O
affect	O
cell	O
death	O
induction	O
in	O
DO11	O
.	O
10	O
-	O
T	O
(	O
Supplementary	O
Fig	O
.	O
7	O
)	O
or	O
isolated	O
DR6	B-GP
-	O
expressing	O
Tfh	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
8	O
).	O

These	O
observations	O
prompted	O
us	O
to	O
test	O
the	O
effect	O
of	O
25	O
-	O
1	O
Ab	O
on	O
disease	O
progression	O
in	O
BWF1	B-OG
mice	I-OG
.	O

We	O
administered	O
25	O
-	O
1	O
Ab	O
(	O
25	O
-	O
1	O
)	O
or	O
nonspecific	O
rat	B-OG
IgG	B-GP
as	O
a	O
control	O
(	O
ctrl	O
-	O
IgG	B-GP
)	O
to	O
15	O
-	O
week	O
-	O
old	O
BWF1	B-OG
mice	I-OG
.	O

Surprisingly	O
,	O
the	O
25	O
-	O
1	O
Ab	O
administrations	O
significantly	O
reduced	O
serum	O
anti	O
-	O
dsDNA	O
Ab	O
production	O
(	O
Fig	O
.	O
5b	O
),	O
the	O
percentage	O
of	O
mice	B-OG
with	O
proteinuria	O
(	O
as	O
a	O
marker	O
for	O
kidney	O
dysfunction	O
;	O
Fig	O
.	O
5c	O
),	O
and	O
improved	O
survival	O
(	O
Fig	O
.	O
5d	O
)	O
compared	O
with	O
the	O
ctrl	O
-	O
IgG	B-GP
administration	O
.	O

In	O
addition	O
,	O
25	O
-	O
1	O
Ab	O
administration	O
significantly	O
reduced	O
the	O
induction	O
of	O
DR6	B-GP
+	O
CD4	B-GP
+	O
cells	O
(	O
Fig	O
.	O
5e	O
),	O
GC	O
B	O
cells	O
(	O
Fig	O
.	O
5f	O
)	O
and	O
plasma	O
cells	O
in	O
BWF1	B-OG
mice	I-OG
(	O
Fig	O
.	O
5g	O
).	O

The	O
splenic	O
cryosections	O
also	O
showed	O
25	O
-	O
1	O
Ab	O
-	O
mediated	O
suppressive	O
effects	O
on	O
GC	O
formation	O
(	O
Fig	O
.	O
5h	O
,	O
i	O
,	O
the	O
results	O
obtained	O
from	O
the	O
other	O
sections	O
represented	O
in	O
Supplementary	O
Fig	O
.	O
9	O
).	O

In	O
addition	O
,	O
we	O
did	O
not	O
observe	O
a	O
significant	O
effect	O
of	O
25	O
-	O
1	O
Ab	O
on	O
antibody	O
dependent	O
cellular	O
cytotoxicity	O
(	O
ADCC	O
,	O
Supplementary	O
Fig	O
.	O
10a	O
)	O
or	O
complement	O
dependent	O
cytotoxicity	O
(	O
CDC	O
,	O
Supplementary	O
Fig	O
.	O
10b	O
).	O

These	O
findings	O
indicate	O
that	O
regulation	O
of	O
DR6	B-GP
delays	O
disease	O
progression	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

Discussion	O

In	O
this	O
current	O
study	O
,	O
we	O
found	O
a	O
disease	O
-	O
specific	O
induction	O
of	O
DR6	B-GP
+	O
T	O
cells	O
in	O
lupus	B-DS
-	O
prone	O
BWF1	B-OG
mice	I-OG
.	O

In	O
particular	O
,	O
the	O
induction	O
of	O
DR6	B-GP
+	O
CD4	B-GP
+	O
T	O
cells	O
correlated	O
with	O
age	O
-	O
and	O
genetic	O
background	O
-	O
dependent	O
disease	O
progression	O
and	O
prognosis	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

A	O
large	O
proportion	O
of	O
CD8	B-GP
+	O
T	O
cells	O
also	O
expressed	O
DR6	B-GP
.	O

However	O
,	O
the	O
expansion	O
of	O
these	O
CD8	B-GP
+	O
T	O
cells	O
was	O
suppressed	O
or	O
not	O
promoted	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

Therefore	O
,	O
we	O
further	O
analysed	O
DR6	B-GP
expressing	O
CD4	B-GP
+	O
T	O
cells	O
.	O

DR6	B-GP
+	O
CD4	B-GP
+	O
cells	O
expressed	O
Il	B-GP
-	I-GP
21	I-GP
and	O
Bcl6	B-GP
.	O

The	O
expression	O
levels	O
were	O
lower	O
than	O
those	O
observed	O
in	O
DR6low	O
Tfh	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
11	O
).	O

The	O
up	O
-	O
regulated	O
expression	O
of	O
DR6	B-GP
on	O
the	O
T	O
cell	O
surface	O
-	O
regulated	O
the	O
threshold	O
of	O
DR6	B-GP
activation	O
to	O
suppress	O
activation	O
of	O
TCR	B-GP
signalling	O
in	O
the	O
cells	O
.	O

However	O
,	O
the	O
up	O
-	O
regulated	O
DR6	B-GP
itself	O
is	O
insufficient	O
for	O
complete	O
prevention	O
of	O
Tfh	O
cells	O
in	O
lupus	B-DS
-	O
prone	O
BWF1	B-OG
mice	I-OG
,	O
because	O
of	O
the	O
low	O
amount	O
of	O
DR6	B-GP
ligand	O
on	O
the	O
surface	O
of	O
GC	O
B	O
cells	O
that	O
are	O
the	O
direct	O
counter	O
partners	O
of	O
the	O
Tfh	O
cells	O
.	O

In	O
addition	O
,	O
recent	O
studies	O
have	O
reported	O
that	O
CD4	B-GP
+	O
T	O
cell	O
populations	O
exhibit	O
disease	O
-	O
associated	O
characteristics	O
caused	O
by	O
several	O
SLE	B-DS
-	O
associated	O
genetic	O
mutations	O
on	O
murine	O
chromosomes	O
1	O
,	O
5	O
,	O
6	O
,	O
7	O
and	O
18	O
,	O
leading	O
to	O
high	O
activation	O
and	O
expansion	O
of	O
CD4	B-GP
+	O
T	O
cell	O
populations	O
in	O
lupus	B-DS
-	O
prone	O
mice37383940	O
.	O

Although	O
the	O
murine	O
Tnfrsf21	B-GP
gene	O
(	O
on	O
chromosome	O
17	O
)	O
is	O
not	O
in	O
murine	O
SLE	B-DS
-	O
associated	O
loci	O
,	O
the	O
unique	O
characteristics	O
of	O
the	O
lupus	B-DS
CD4	B-GP
+	O
T	O
cell	O
populations	O
emphasize	O
the	O
importance	O
of	O
DR6	B-GP
functions	O
in	O
the	O
regulation	O
of	O
CD4	B-GP
+	O
T	O
cells	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

Upregulation	O
of	O
DR6	B-GP
expression	O
was	O
observed	O
in	O
Tfh	O
cell	O
populations	O
of	O
lupus	B-DS
-	O
prone	O
BWF1	B-OG
mice	I-OG
.	O

In	O
contrast	O
to	O
lupus	B-DS
-	O
prone	O
mice	B-OG
,	O
DR6	B-GP
expression	O
was	O
low	O
in	O
Tfh	O
cells	O
of	O
DNP	O
-	O
KLH	O
-	O
immunized	O
mice	B-OG
(	O
Supplementary	O
Fig	O
.	O
12a	O
,	O
b	O
,	O
vertical	O
axes	O
).	O

CXCR4	B-GP
(	O
Supplementary	O
Fig	O
.	O
12b	O
,	O
horizontal	O
axes	O
)	O
or	O
Bcl6	B-GP
(	O
Supplementary	O
Fig	O
.	O
12c	O
)	O
expression	O
in	O
these	O
cells	O
was	O
also	O
low	O
compared	O
with	O
that	O
in	O
Tfh	O
cells	O
of	O
BWF1	B-OG
mice	I-OG
.	O

Collectively	O
,	O
Tfh	O
cells	O
of	O
lupus	B-DS
-	O
prone	O
mice	B-OG
manifested	O
their	O
pathological	O
characteristics	O
compared	O
with	O
Tfh	O
cells	O
of	O
healthy	O
mice	B-OG
as	O
expected	O
,	O
considering	O
that	O
lupus	B-DS
CD4	B-GP
+	O
T	O
cell	O
populations	O
have	O
a	O
high	O
sensitivity	O
to	O
TCR	B-GP
activation3739	O
.	O

The	O
TCR	B-GP
signal	O
promoted	O
high	O
DR6	B-GP
induction	O
on	O
Tfh	O
cells	O
of	O
lupus	B-DS
-	O
prone	O
mice	B-OG
(	O
Supplementary	O
Fig	O
.	O
13a	O
,	O
b	O
).	O

Recently	O
,	O
these	O
pathological	O
characteristics	O
of	O
lupus	B-DS
CD4	B-GP
+	O
T	O
cells	O
were	O
shown	O
to	O
be	O
caused	O
by	O
aberrant	O
metabolic	O
regulations	O
,	O
and	O
are	O
crucial	O
for	O
spontaneous	O
induction	O
of	O
Tfh	O
cell	O
generation	O
,	O
GC	O
formation	O
,	O
and	O
disease	O
symptoms	O
in	O
lupus	B-DS
-	O
prone	O
mice38	O
.	O

Interestingly	O
,	O
such	O
aberrant	O
regulation	O
of	O
lupus	B-DS
CD4	B-GP
+	O
T	O
cells	O
is	O
not	O
associated	O
with	O
humoral	O
responses	O
against	O
foreign	O
antigens38	O
.	O

Therefore	O
,	O
the	O
pathological	O
cellular	O
characteristics	O
might	O
involve	O
high	O
DR6	B-GP
induction	O
on	O
auto	O
reactive	O
Tfh	O
cells	O
of	O
severe	O
lupus	B-DS
-	O
prone	O
BWF1	B-OG
mice	I-OG
.	O

We	O
characterized	O
syndecan	B-GP
-	I-GP
1	I-GP
as	O
a	O
binding	O
partner	O
for	O
DR6	B-GP
.	O

Recombinant	O
syndecan	B-GP
-	I-GP
1	I-GP
stimulation	O
was	O
not	O
capable	O
of	O
inducing	O
cell	O
death	O
,	O
except	O
when	O
it	O
was	O
highly	O
concentrated	O
(	O
Supplementary	O
Fig	O
.	O
4	O
).	O

This	O
weak	O
apoptotic	O
effect	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
stimulation	O
is	O
consistent	O
with	O
the	O
weak	O
apoptotic	O
capability	O
of	O
DR6	B-GP
compared	O
with	O
that	O
of	O
the	O
other	O
TNFRSF	B-GP
molecules	O
,	O
such	O
as	O
death	B-GP
receptor	I-GP
-	I-GP
4	I-GP
(	O
DR4	B-GP
)	O
17	O
and	O
-	O
3	O
(	O
DR3	B-GP
)	O
41	O
.	O

This	O
weak	O
apoptotic	O
activity	O
of	O
DR6	B-GP
might	O
depend	O
on	O
its	O
low	O
affinities	O
of	O
binding	O
to	O
Fas	B-GP
-	I-GP
associated	I-GP
protein	I-GP
with	I-GP
death	I-GP
domain	I-GP
(	O
FADD	B-GP
)	O
and	O
TNFR	B-GP
-	I-GP
associated	I-GP
death	I-GP
domain	I-GP
protein	I-GP
(	O
TRADD	B-GP
),	O
which	O
are	O
key	O
components	O
for	O
apoptotic	O
caspase	B-GP
activation17	O
.	O

In	O
addition	O
,	O
DR6	B-GP
receptor	O
cross	O
-	O
linking	O
did	O
not	O
affect	O
caspase	B-GP
activation	O
in	O
the	O
cultured	O
T	O
-	O
cell	O
line	O
(	O
Supplementary	O
Fig	O
.	O
14	O
).	O

Meanwhile	O
,	O
syndecan	B-GP
-	I-GP
1	I-GP
/	O
DR6	B-GP
interaction	O
dramatically	O
suppressed	O
the	O
activation	O
of	O
TCR	B-GP
signalling	O
,	O
which	O
activates	O
NFÎºB	B-GP
and	O
NFAT	B-GP
in	O
the	O
present	O
study	O
.	O

In	O
addition	O
,	O
DR6	B-GP
gene	O
deficiency	O
in	O
lymphocytes	O
leads	O
to	O
hyper	O
activation	O
of	O
NFÎºB	B-GP
or	O
NFAT1920	O
.	O

These	O
findings	O
and	O
our	O
data	O
suggest	O
that	O
DR6	B-GP
regulates	O
lymphocyte	O
activation	O
by	O
its	O
negative	O
regulation	O
to	O
NFÎºB	B-GP
and	O
NFAT	B-GP
signalling	O
rather	O
than	O
apoptotic	O
function	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
of	O
this	O
DR6	B-GP
-	O
mediated	O
suppression	O
have	O
yet	O
to	O
be	O
elucidated	O
.	O

Syndecan	B-GP
-	I-GP
1	I-GP
has	O
multiple	O
functions	O
in	O
immunological	O
events	O
and	O
disease	O
progression27	O
.	O

Syndecan	B-GP
-	I-GP
1	I-GP
can	O
attach	O
to	O
several	O
chemokines	B-GP
,	O
growth	O
factors	O
,	O
and	O
cytokines	B-GP
,	O
suggesting	O
that	O
it	O
has	O
a	O
scaffolding	O
function	O
for	O
the	O
accumulation	O
of	O
inflammatory	O
cells	O
in	O
localized	O
inflammation	O
.	O

Several	O
knockout	O
studies	O
also	O
suggest	O
that	O
syndecan	B-GP
-	I-GP
1	I-GP
regulates	O
antibody	O
production	O
.	O

Syndecan	B-GP
-	I-GP
1	I-GP
deficiency	O
induces	O
pathogenic	O
antigen	O
(	O
myelin	B-GP
oligodendrocyte	I-GP
glycoprotein	I-GP
)-	O
specific	O
plasma	O
cells	O
in	O
an	O
EAE	B-DS
model28	O
.	O

Syndecan	B-GP
-	I-GP
1	I-GP
deficiency	O
also	O
causes	O
high	O
immunoglobulin	B-GP
production	O
in	O
an	O
Ab	O
-	O
dependent	O
nephritis	B-DS
model29	O
.	O

Importantly	O
,	O
DR6	B-GP
is	O
also	O
associated	O
with	O
negative	O
regulation	O
of	O
peripheral	O
lymphocyte	O
activation	O
in	O
syndecan	B-GP
-	I-GP
1	I-GP
-	O
associated	O
immunological	B-DS
disease	I-DS
models	O
such	O
as	O
EAE21	O
,	O
lung	B-DS
inflammation22	I-DS
,	O
and	O
lupus	B-DS
-	O
like	O
disease	O
(	O
the	O
present	O
study	O
).	O

These	O
findings	O
suggest	O
an	O
association	O
of	O
DR6	B-GP
/	O
syndecan	B-GP
-	I-GP
1	I-GP
interaction	O
with	O
the	O
progression	O
of	O
several	O
immunological	B-DS
diseases	I-DS
.	O

The	O
25	O
-	O
1	O
Ab	O
was	O
capable	O
of	O
DR6	B-GP
cross	O
-	O
linking	O
.	O

Recombinant	O
syndecan	B-GP
-	I-GP
1	I-GP
,	O
as	O
well	O
as	O
25	O
-	O
1	O
Ab	O
treatment	O
,	O
suppressed	O
Il	B-GP
-	I-GP
21	I-GP
production	O
by	O
Tfh	O
cells	O
.	O

Therefore	O
,	O
the	O
antibody	O
should	O
mimic	O
the	O
function	O
of	O
syndecan	B-GP
-	I-GP
1	I-GP
that	O
was	O
reduced	O
in	O
BWF1	B-OG
mice	I-OG
.	O

IL	B-GP
-	I-GP
21	I-GP
production	O
by	O
Tfh	O
cells	O
is	O
critical	O
for	O
both	O
maintenance	O
and	O
development	O
of	O
GC	O
B	O
cells42	O
.	O

Although	O
the	O
importance	O
of	O
IL	B-GP
-	I-GP
21	I-GP
production	O
in	O
Tfh	O
cell	O
development	O
is	O
controversial43	O
,	O
GC	O
B	O
/	O
Tfh	O
cell	O
interaction	O
is	O
important	O
for	O
full	O
-	O
maturation	O
and	O
maintenance	O
of	O
Tfh	O
cells	O
and	O
GC	O
formation94445	O
.	O

Therefore	O
,	O
25	O
-	O
1	O
Ab	O
or	O
syndecan	B-GP
-	I-GP
1	I-GP
should	O
fine	O
-	O
tune	O
the	O
outcome	O
of	O
GC	O
B	O
/	O
Tfh	O
cell	O
interactions	O
,	O
to	O
prevent	O
autoantibody	O
production	O
and	O
disease	O
progression	O
in	O
BWF1	B-OG
mice	I-OG
.	O

Moreover	O
,	O
although	O
25	O
-	O
1	O
Ab	O
preferentially	O
bound	O
to	O
CD3	B-GP
+	O
T	O
cells	O
,	O
other	O
cells	O
binding	O
25	O
-	O
1	O
Ab	O
were	O
also	O
observed	O
in	O
total	O
splenocytes	O
obtained	O
from	O
BWF1	B-OG
mice	I-OG
.	O

Several	O
reports	O
have	O
shown	O
DR6	B-GP
expression	O
on	O
B	O
cells	O
,	O
dendritic	O
cells	O
and	O
macrophages194647	O
.	O

In	O
addition	O
,	O
these	O
cells	O
are	O
associated	O
with	O
GC	O
reactions	O
after	O
immunization	O
in	O
healthy	O
mice	B-OG
,	O
as	O
well	O
as	O
the	O
disease	O
progression	O
of	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

Therefore	O
,	O
further	O
studies	O
will	O
be	O
needed	O
to	O
investigate	O
the	O
role	O
of	O
DR6	B-GP
/	O
syndecan	B-GP
-	I-GP
1	I-GP
interaction	O
in	O
the	O
regulation	O
of	O
these	O
cells	O
in	O
the	O
immunization	O
as	O
well	O
as	O
the	O
disease	O
progression	O
.	O

Taken	O
together	O
,	O
in	O
the	O
current	O
study	O
,	O
we	O
identified	O
a	O
novel	O
regulatory	O
mechanism	O
that	O
depends	O
on	O
the	O
interaction	O
of	O
DR6	B-GP
with	O
syndecan	B-GP
-	I-GP
1	I-GP
for	O
preventing	O
expansion	O
and	O
activation	O
of	O
Tfh	O
cells	O
and	O
disease	O
progression	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O

Therefore	O
,	O
the	O
DR6	B-GP
/	O
syndecan	B-GP
-	I-GP
1	I-GP
axis	O
should	O
be	O
a	O
novel	O
therapeutic	O
target	O
in	O
autoimmune	B-DS
disease	I-DS
.	O

Methods	O

Mice	B-OG

Female	O
C57BL	O
/	O
6	O
,	O
New	O
Zealand	O
Black	O
(	O
NZB	O
),	O
or	O
NZB	O
Ã	O
New	O
Zealand	O
White	O
F1	O
mice	B-OG
were	O
purchased	O
from	O
SLC	O
Inc	O
.	O

(	O
Shizuoka	O
,	O
Japan	O
).	O

These	O
mice	B-OG
were	O
housed	O
in	O
specific	O
pathogen	O
-	O
free	O
conditions	O
.	O

All	O
mice	B-OG
were	O
assigned	O
randomly	O
to	O
experimental	O
groups	O
.	O

We	O
performed	O
animal	B-OG
care	O
and	O
experiments	O
in	O
accordance	O
with	O
the	O
guidelines	O
and	O
approval	O
of	O
the	O
Animal	B-OG
Care	O
and	O
Use	O
Committee	O
of	O
Hokkaido	O
University	O
.	O

Cells	O

Murine	O
fibrosarcoma	B-DS
L929	O
,	O
human	B-OG
embryonic	O
fibroblast	O
(	O
HEK	O
)	O
293T	O
cells	O
,	O
and	O
retrovirus	B-OG
packaging	O
cells	O
(	O
PLAT	O
-	O
E	O
,	O
kindly	O
provided	O
by	O
Dr	O
Kitamura	O
T	O
)	O
were	O
maintained	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
containing	O
10	O
%	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
at	O
37	O
Â°	O
C	O
in	O
5	O
%	O
CO2	O
.	O

Murine	O
T	O
cell	O
hybridoma	O
DO11	O
.	O
10	O
-	O
T	O
and	O
murine	O
lymphoma	B-DS
A20	O
were	O
also	O
maintained	O
in	O
RPMI	O
-	O
1640	O
medium	O
containing	O
10	O
%	O
FCS	O
.	O

All	O
cell	O
lines	O
were	O
routinely	O
tested	O
for	O
mycoplasma	B-OG
.	O

Generation	O
of	O
recombinant	O
proteins	O

For	O
construction	O
of	O
DR6	B-GP
-	O
Fc	O
,	O
cDNA	O
encoding	O
the	O
extracellular	O
region	O
of	O
DR6	B-GP
(	O
mouse	B-OG
:	O
from	O
+	O
1_	O
+	O
350	O
aa	O
)	O
was	O
fused	O
with	O
the	O
Fc	O
region	O
of	O
human	B-OG
IgG	B-GP
,	O
which	O
was	O
mutated	O
at	O
the	O
amino	O
acid	O
position	O
of	O
E233P	O
,	O
L234A	O
,	O
and	O
L235A	O
for	O
preventing	O
binding	O
with	O
mouse	B-OG
Fc	B-GP
receptors	I-GP
,	O
and	O
inserted	O
into	O
pcDNA3	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
).	O

The	O
resulted	O
plasmid	O
was	O
transfected	O
into	O
HEK293T	O
cells	O
with	O
lipofectamine	O
2000	O
(	O
Life	O
Technologies	O
).	O

The	O
recombinant	O
protein	O
secreted	O
in	O
the	O
cultured	O
supernatant	O
was	O
purified	O
by	O
protein	B-GP
-	I-GP
A	I-GP
sepharose	O
column48	O
.	O

Biotinylation	O
of	O
the	O
proteins	O
was	O
performed	O
using	O
the	O
EZ	O
-	O
Link	O
NHS	O
-	O
PEO	O
Solid	O
Phase	O
Biotinylation	O
Kit	O
(	O
Life	O
Technologies	O
),	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

For	O
the	O
generation	O
of	O
recombinant	O
mouse	B-OG
syndecan	B-GP
-	I-GP
1	I-GP
protein	O
(	O
recSdc1	O
),	O
the	O
cDNA	O
encoding	O
ectodomain	O
of	O
mouse	B-OG
syndecan	B-GP
-	I-GP
1	I-GP
(+	O
1_	O
+	O
251	O
aa	O
)	O
was	O
inserted	O
into	O
pcDNA3	O
.	O
1	O
myc	O
/	O
his	O
ver	O
.	O
B	O
(	O
Life	O
Technologies	O
).	O

The	O
production	O
of	O
recSdc1	O
that	O
was	O
fused	O
with	O
hexamer	O
His	O
tags	O
was	O
achieved	O
in	O
HEK293T	O
cells	O
as	O
described	O
above	O
.	O

RecSdc1	O
in	O
culture	O
medium	O
was	O
purified	O
using	O
Ni	O
-	O
sepharose	O
column	O
(	O
HisTrap	O
HP	O
,	O
GE	O
Healthcare	O
,	O
Piscataway	O
,	O
NJ	O
).	O

Generation	O
of	O
anti	O
-	O
DR6	B-GP
specific	O
monoclonal	O
antibody	O

Hybridomas	O
were	O
generated	O
from	O
splenocytes	O
of	O
Lewis	B-OG
rats	I-OG
immunized	O
with	O
DR6	B-GP
-	O
Fc	O
and	O
L929	O
-	O
mDR6	O
cells	O
.	O

Specificity	O
of	O
the	O
antibody	O
produced	O
in	O
the	O
cells	O
was	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
DR6	B-GP
-	O
Fc	O
or	O
human	B-OG
IgG	B-GP
as	O
antigen	O
.	O

Flow	O
cytometry	O

Details	O
of	O
antibodies	O
used	O
in	O
the	O
present	O
study	O
are	O
listed	O
in	O
Supplementary	O
Table	O
1	O
.	O

For	O
analysing	O
cell	O
surface	O
molecules	O
,	O
single	O
-	O
cell	O
suspensions	O
were	O
stained	O
with	O
the	O
indicated	O
antibodies	O
(	O
the	O
concentration	O
of	O
antibody	O
is	O
also	O
listed	O
in	O
Supplementary	O
Table	O
1	O
),	O
after	O
Fc	O
-	O
block	O
with	O
anti	O
-	O
CD16	B-GP
/	O
32	O
(	O
clone	O
2	O
.	O
4G2	O
,	O
20	O
Î¼g	O
ml	O
â	O
l	O
,	O
4	O
Â°	O
C	O
,	O
15	O
min	O
).	O

After	O
washed	O
twice	O
with	O
ice	O
-	O
cold	O
PBS	O
containing	O
0	O
.	O
5	O
%	O
bovine	O
serum	O
albumin	B-GP
and	O
0	O
.	O
1	O
%	O
NaN3	O
,	O
the	O
cells	O
were	O
further	O
stained	O
with	O
7AAD	O
.	O

Fluorescent	O
intensities	O
of	O
the	O
cells	O
were	O
detected	O
on	O
a	O
LSR	O
Fortessa	O
or	O
Canto	O
(	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
CA	O
).	O

For	O
identifying	O
lymphocyte	O
cell	O
populations	O
that	O
were	O
indicated	O
in	O
each	O
figure	O
,	O
gate	O
strategies	O
were	O
shown	O
in	O
Supplementary	O
Fig	O
.	O
15	O
.	O

For	O
intracellular	O
Bcl6	B-GP
detection49	O
,	O
Fixable	O
Viability	O
Dye	O
eFluor	O
780	O
(	O
eBioscience	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
was	O
used	O
instead	O
of	O
7AAD	O
.	O

Expression	O
screening	O

Expression	O
screening	O
using	O
the	O
retrovirus	B-OG
-	O
based	O
full	O
-	O
length	O
cDNA	O
library	O
was	O
performed	O
as	O
described	O
in	O
our	O
previous	O
report50	O
.	O

Briefly	O
,	O
the	O
full	O
-	O
length	O
cDNA	O
library	O
was	O
constructed	O
using	O
the	O
In	O
-	O
Fusion	O
SMARTer	O
Directional	O
cDNA	O
Library	O
construction	O
kit	O
(	O
Takara	O
Bio	O
,	O
Shiga	O
,	O
Japan	O
)	O
and	O
inserted	O
into	O
retrovirus	B-OG
vector	O
,	O
pMXs51	O
.	O

The	O
titer	O
of	O
cDNA	O
library	O
was	O
>	O
1	O
Ã	O
106	O
plaque	O
forming	O
units	O
per	O
ml	O
,	O
and	O
>	O
90	O
%	O
of	O
individual	O
clones	O
contained	O
different	O
cDNA	O
fragments	O
.	O

pMXs	O
containing	O
cDNA	O
library	O
was	O
retrovirally	O
packaged	O
in	O
PLAT	O
-	O
E	O
cells	O
.	O

DO11	O
.	O
10	O
-	O
T	O
cell	O
hybridoma	O
(	O
2	O
Ã	O
106	O
cells	O
)	O
was	O
infected	O
with	O
the	O
virus	O
particles	O
at	O
a	O
multiplicity	O
of	O
infection	B-DS
=	O
0	O
.	O
1	O
.	O

Two	O
days	O
after	O
the	O
infection	B-DS
,	O
the	O
cells	O
were	O
stained	O
with	O
biotinylated	O
DR6	B-GP
-	O
Fc	O
plus	O
streptavidin	B-GP
-	O
allophycocyanin	B-GP
(	O
APC	B-GP
).	O

After	O
two	O
-	O
washes	O
,	O
APC	B-GP
-	O
positive	O
cells	O
were	O
sorted	O
by	O
MoFlo	O
Astrios	O
(	O
Beckman	O
Coulter	O
,	O
Brea	O
,	O
CA	O
).	O

The	O
sorted	O
cells	O
were	O
then	O
expanded	O
.	O

After	O
five	O
-	O
rounds	O
of	O
sorting	O
and	O
culturing	O
,	O
the	O
provirus	O
in	O
the	O
sorted	O
cells	O
was	O
isolated	O
by	O
PCR	O
using	O
pMXs	O
-	O
specific	O
primer	O
set	O
.	O

Stable	O
gene	O
expression	O

cDNA	O
fragment	O
encoding	O
the	O
indicated	O
gene	O
was	O
cloned	O
into	O
pMXsIG51	O
at	O
multiple	O
cloning	O
sites	O
.	O

The	O
construct	O
was	O
retrovirally	O
transfected	O
into	O
cells	O
.	O

Among	O
the	O
cells	O
,	O
enhanced	O
green	B-GP
fluorescent	I-GP
protein	I-GP
positive	O
cells	O
were	O
sorted	O
by	O
Moflo	O
Astrios	O
.	O

The	O
purity	O
of	O
the	O
cells	O
was	O
confirmed	O
as	O
>	O
90	O
%	O
by	O
flow	O
cytometry	O
.	O

Tnfrsf21	B-GP
knockout	O
single	O
cell	O
clone	O

The	O
23	O
nucleotide	O
guide	O
sequence	O
(	O
5	O
â²-	O
CCACGATGGTCGCCGGCTCTCTT	O
-	O
3	O
â²	O
)	O
targeting	O
on	O
negative	O
strand	O
genomic	O
DNA	O
locating	O
on	O
exon	O
-	O
1	O
of	O
murine	O
Tnfrsf21	B-GP
gene	O
was	O
designed	O
with	O
CRISPR	O
direct	O
software	O
uploaded	O
in	O
http	O
://	O
crispr	O
.	O
dbcls	O
.	O
jp	O
.	O

The	O
DNA	O
fragment	O
was	O
cloned	O
into	O
pSpCas9	O
(	O
BB	O
)-	O
2A	O
-	O
Puro	O
(	O
PX459	O
)	O
ver	O
.	O
2	O
(	O
ref	O
.	O
52	O
).	O

The	O
resulted	O
plasmid	O
was	O
electroporated	O
into	O
DO11	O
.	O
10	O
-	O
T	O
cell	O
using	O
Gene	O
Pulser	O
X	O
-	O
cell	O
(	O
Bio	O
-	O
Rad	O
,	O
Hemel	O
Hempstead	O
,	O
UK	O
)	O
at	O
280	O
V	O
and	O
950	O
Î¼F	O
.	O

Two	O
days	O
after	O
puromycin	O
selection	O
at	O
3	O
Î¼g	O
ml	O
â	O
1	O
,	O
single	O
cell	O
clones	O
of	O
the	O
cells	O
were	O
isolated	O
by	O
limiting	O
dilution	O
.	O

The	O
single	O
cell	O
clones	O
were	O
selected	O
after	O
their	O
re	O
-	O
exhibition	O
of	O
puromycin	O
sensitivity	O
(	O
for	O
validating	O
plasmid	O
exclusion	O
)	O
and	O
sequencing	O
their	O
genomic	O
DNA	O
(	O
for	O
gene	O
editing	O
).	O

Quantitative	O
PCR	O

Quantitative	O
PCR	O
assay	O
was	O
performed	O
using	O
SYBR	O
Premix	O
Ex	O
Taq	O
II	O
(	O
Takara	O
Bio	O
.)	O
41	O
.	O

Briefly	O
,	O
cellular	O
total	O
RNAs	O
were	O
isolated	O
by	O
Trizol	O
method	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
(	O
Life	O
Technologies	O
).	O

Reverse	O
-	O
transcription	O
was	O
carried	O
out	O
by	O
using	O
ReverTra	O
Ace	O
(	O
Toyobo	O
CO	O
.	O

Ltd	O
.,	O
Osaka	O
,	O
Japan	O
).	O

Gene	O
-	O
specific	O
primer	O
sets	O
used	O
in	O
the	O
current	O
study	O
are	O
shown	O
in	O
Supplementary	O
Table	O
2	O
.	O

Mean	O
of	O
Actb	B-GP
in	O
each	O
sample	O
was	O
used	O
as	O
internal	O
control	O
.	O

Site	O
-	O
directed	O
mutagenesis	O

For	O
generating	O
region	O
specific	O
deletion	O
mutants	O
of	O
DR6	B-GP
(	O
ÎCRD1	O
;	O
deleted	O
the	O
region	O
from	O
+	O
42	O
to	O
+	O
105	O
aa	O
,	O
ÎCRD2	O
;	O
deleted	O
the	O
region	O
from	O
+	O
106	O
to	O
+	O
145	O
aa	O
,	O
ÎCRD3	O
;	O
deleted	O
the	O
region	O
from	O
+	O
146	O
to	O
+	O
185	O
aa	O
or	O
ÎCRD4	O
;	O
deleted	O
the	O
region	O
from	O
+	O
186	O
to	O
+	O
212	O
aa	O
),	O
site	O
-	O
directed	O
deletions	O
were	O
introduced	O
into	O
the	O
plasmid	O
encoding	O
DR6	B-GP
-	O
Fc	O
using	O
PrimeSTAR	O
Mutagenesis	O
kit	O
(	O
Takara	O
Bio	O
.)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

Pull	O
down	O
assay	O

A20	O
cells	O
(	O
2	O
.	O
5	O
Ã	O
107	O
cells	O
)	O
were	O
incubated	O
with	O
the	O
indicated	O
Fc	O
fused	O
protein	O
(	O
10	O
Î¼g	O
ml	O
â	O
1	O
)	O
at	O
4	O
Â°	O
C	O
.	O

Two	O
hours	O
after	O
the	O
incubation	O
,	O
cells	O
were	O
washed	O
three	O
times	O
with	O
ice	O
-	O
cold	O
culture	O
medium	O
and	O
lysed	O
with	O
the	O
lysis	O
buffer	O
containing	O
0	O
.	O
2	O
%	O
NP	O
-	O
40	O
,	O
10	O
%	O
Glycerol	O
,	O
150	O
mM	O
NaCl	O
and	O
20	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
at	O
4	O
Â°	O
C	O
.	O

After	O
centrifugation	O
(	O
20	O
,	O
000	O
Ã	O
g	O
,	O
30	O
min	O
,	O
4	O
Â°	O
C	O
),	O
the	O
supernatant	O
was	O
precipitated	O
with	O
protein	B-GP
A	I-GP
sepharose	O
beads	O
(	O
GE	O
Healthcare	O
)	O
at	O
4	O
Â°	O
C	O
for	O
2	O
h	O
.	O

The	O
beads	O
were	O
washed	O
three	O
times	O
with	O
the	O
lysis	O
buffer	O
and	O
the	O
eluted	O
materials	O
were	O
analysed	O
by	O
dot	O
blot	O
assay	O
using	O
anti	O
-	O
syndecan	B-GP
-	I-GP
1	I-GP
Ab	O
(	O
clone	O
281	O
-	O
1	O
,	O
1	O
/	O
1	O
,	O
000	O
diluted	O
,	O
Biolegend	O
,	O
San	O
Diego	O
,	O
CA	O
).	O

Reporter	O
gene	O
assay	O

Cells	O
(	O
3	O
Ã	O
106	O
cells	O
per	O
450	O
Î¼l	O
of	O
Opti	O
-	O
MEM	O
(	O
Life	O
Technologies	O
)	O
in	O
a	O
0	O
.	O
4	O
-	O
cm	O
cuvette	O
)	O
were	O
electroporated	O
with	O
20	O
Î¼g	O
firefly	B-OG
-	O
luciferase	B-GP
reporter	O
plasmid	O
(	O
pGL4	O
.	O
26	O
,	O
Promega	O
)	O
containing	O
binding	O
motif	O
for	O
the	O
indicated	O
transcriptional	O
factor	O
plus	O
5	O
Î¼g	O
reference	O
renilla	B-OG
-	O
luciferase	B-GP
reporter	O
plasmid	O
(	O
phRG	O
-	O
TK	O
,	O
Promega	O
)	O
as	O
described	O
above	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
the	O
electroporation	O
,	O
cells	O
were	O
stimulated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	B-GP
Ab	O
(	O
10	O
Î¼g	O
ml	O
â	O
1	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
recSdc1	O
(	O
30	O
nM	O
).	O

Six	O
hours	O
after	O
the	O
stimulation	O
,	O
the	O
luciferase	B-GP
activities	O
of	O
the	O
cells	O
were	O
assessed	O
by	O
dual	O
-	O
Glo	O
luciferase	B-GP
assay	O
(	O
Promega	O
).	O

ELISA	O

The	O
amount	O
of	O
mouse	B-OG
IL	B-GP
-	I-GP
2	I-GP
was	O
assessed	O
by	O
mouse	B-OG
IL	B-GP
-	I-GP
2	I-GP
Quantikine	O
ELISA	O
kit	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
(	O
M2000	O
,	O
R	O
&	O
D	O
systems	O
,	O
Minneapolis	O
,	O
MN	O
).	O

Immunohistochemistry	O

Acetone	O
-	O
fixed	O
cryosections	O
(	O
7	O
Î¼m	O
)	O
were	O
blocked	O
by	O
immunoblock	O
(	O
DS	O
Pharma	O
Biomedical	O
,	O
Osaka	O
,	O
Japan	O
)	O
and	O
then	O
stained	O
with	O
the	O
indicated	O
Abs	O
.	O

The	O
dilution	O
of	O
each	O
antibody	O
is	O
shown	O
in	O
Supplementary	O
Table	O
1	O
.	O

Fluorescent	O
images	O
of	O
the	O
sections	O
were	O
captured	O
on	O
a	O
confocal	O
laser	O
scanning	O
system	O
(	O
LSM	O
-	O
780	O
,	O
Carl	O
Zeiss	O
Microscopy	O
GmbH	O
,	O
GÃ¶ttingen	O
,	O
Germany	O
).	O

GL7	B-GP
+	O
area	O
in	O
the	O
field	O
was	O
calculated	O
using	O
ImageJ	O
software	O
.	O

Detection	O
of	O
anti	O
-	O
dsDNA	O
antibody	O

Anti	O
-	O
dsDNA	O
Ab	O
in	O
serum	O
sample	O
was	O
detected	O
by	O
ELISA	O
using	O
double	O
-	O
stranded	O
deoxyribonucleic	O
acid	O
coated	O
plate	O
and	O
horse	B-OG
radish	I-OG
peroxidase	B-GP
conjugated	O
goat	B-OG
anti	O
-	O
mouse	B-OG
IgG	B-GP
(	O
H	O
+	O
L	O
)	O
antibody	O
(	O
1	O
/	O
5	O
,	O
000	O
diluted	O
,	O
Jackson	O
Immuno	O
Research	O
,	O
West	O
Grove	O
,	O
PA	O
).	O

Detection	O
of	O
proteinuria	O

Uropaper	O
III	O
strip	O
(	O
Eiken	O
Chemical	O
Co	O
.,	O
Tochigi	O
,	O
Japan	O
)	O
was	O
used	O
for	O
urinalysis	O
.	O

Proteinuria	O
was	O
defined	O
as	O
urinary	O
protein	O
excretion	O
exceeding	O
100	O
mg	O
dl	O
â	O
1	O
.	O

Statistical	O
analysis	O

Two	O
sets	O
of	O
data	O
were	O
compared	O
using	O
two	O
-	O
tailed	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

When	O
variances	O
were	O
not	O
comparable	O
,	O
Welch	O
'	O
s	O
correction	O
was	O
applied	O
.	O

Sample	O
sizes	O
were	O
selected	O
based	O
on	O
the	O
number	O
of	O
replicates	O
(	O
up	O
to	O
three	O
).	O

For	O
survival	O
rate	O
or	O
cumulative	O
incidence	O
,	O
statistical	O
analysis	O
was	O
performed	O
by	O
Log	O
-	O
rank	O
test	O
or	O
Grey	O
test	O
with	O
R	O
software	O
(	O
http	O
://	O
www	O
.	O
R	O
-	O
project	O
.	O
org	O
).	O
P	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

Asterisk	O
or	O
NS	O
means	O
â	O
significant	O
'	O
or	O
â	O
not	O
significant	O
',	O
respectively	O
.	O

Each	O
in	O
vitro	O
experiment	O
was	O
performed	O
at	O
least	O
twice	O
with	O
reproducible	O
results	O
.	O

Data	O
availability	O

The	O
authors	O
declare	O
that	O
the	O
data	O
supporting	O
of	O
the	O
findings	O
of	O
this	O
study	O
are	O
available	O
within	O
the	O
article	O
and	O
its	O
Supplementary	O
Information	O
Files	O
,	O
or	O
from	O
the	O
corresponding	O
authors	O
on	O
reasonable	O
request	O
.	O

Additional	O
information	O

How	O
to	O
cite	O
this	O
article	O
:	O
Fujikura	O
,	O
D	O
.	O
et	O
al	O
.	O

Death	B-GP
receptor	I-GP
6	I-GP
contributes	O
to	O
autoimmunity	O
in	O
lupus	B-DS
-	O
prone	O
mice	B-OG
.	O
Nat	O
.	O

Commun	O
.	O
8	O
,	O
13957	O
doi	O
:	O
10	O
.	O
1038	O
/	O
ncomms13957	O
(	O
2017	O
).	O

Publisher	O
'	O
s	O
note	O
:	O
Springer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

Supplementary	O
Material	O

Supplementary	O
Information	O

Supplementary	O
Figures	O
,	O
Supplementary	O
Tables	O
,	O
Supplementary	O
Methods	O
and	O
Supplementary	O
References	O

D	O
.	O
F	O
.	O
and	O
T	O
.	O
U	O
.	O
have	O
filed	O
an	O
application	O
under	O
the	O
Patent	O
Cooperation	O
Treaty	O
(	O
PCT	O
),	O
WO2015076282	O
A1	O
,	O
â	O
Immunosuppressant	O
'	O
regarding	O
the	O
studies	O
in	O
the	O
current	O
paper	O
.	O

The	O
remaining	O
authors	O
declare	O
no	O
competing	O
financial	O
interests	O
.	O

Author	O
contributions	O
D	O
.	O
F	O
.	O
and	O
T	O
.	O
U	O
.	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

D	O
.	O
F	O
.,	O
M	O
.	O
I	O
.,	O
T	O
.	O
E	O
.	O
and	O
S	O
.	O
C	O
.	O
performed	O
the	O
experiments	O
.	O

D	O
.	O
F	O
.	O
analysed	O
the	O
data	O
.	O

H	O
.	O
H	O
.	O
gave	O
technical	O
advice	O
.	O

D	O
.	O
F	O
.	O
and	O
T	O
.	O
U	O
.	O
wrote	O
the	O
paper	O
.	O

Total	O
splenocytes	O
obtained	O
from	O
the	O
indicated	O
mice	O
were	O
stained	O
with	O
anti	O
-	O
DR6	O
specific	O
monoclonal	O
antibody	O
(	O
clone	O
25	O
-	O
1	O
)	O
with	O
anti	O
-	O
CD3	O
,	O
CD8	O
and	O
CD4	O
specific	O
Abs	O
.	O

(	O
a	O
)	O
Total	O
splenocytes	O
(	O
gated	O
as	O
live	O
singlet	O
cells	O
shown	O
in	O
Supplementary	O
Fig	O
.	O
15a	O
)	O
were	O
analysed	O
on	O
CD3	O
versus	O
DR6	O
dot	O
plot	O
.	O

Numbers	O
in	O
the	O
dot	O
plots	O
indicates	O
percentage	O
of	O
the	O
cells	O
gated	O
.	O

(	O
b	O
)	O
CD4	O
+	O
T	O
cells	O
(	O
CD3	O
+	O
CD8	O
â	O
CD4	O
+)	O
of	O
the	O
total	O
splenocytes	O
were	O
also	O
analysed	O
on	O
CD4	O
versus	O
DR6	O
dot	O
plots	O
.	O

(	O
c	O
)	O
Quantification	O
of	O
the	O
percentage	O
of	O
DR6	O
+	O
cells	O
in	O
the	O
CD4	O
+	O
T	O
cells	O
.	O

Error	O
bars	O
represent	O
standard	O
deviation	O
(	O
s	O
.	O
d	O
.)	O
(	O
n	O
=	O
5	O
per	O
group	O
).	O

(	O
d	O
)	O
CD8	O
+	O
T	O
cells	O
(	O
CD3	O
+	O
CD8	O
+	O
CD4	O
â)	O
of	O
splenocytes	O
of	O
the	O
indicated	O
mice	O
were	O
analysed	O
on	O
CD8	O
versus	O
DR6	O
dot	O
plots	O
.	O

(	O
e	O
)	O
DR6	O
expression	O
(	O
median	O
of	O
fluorescent	O
intensity	O
,	O
MFI	O
)	O
on	O
CD8	O
+	O
T	O
cells	O
was	O
also	O
quantified	O
.	O

(	O
f	O
)	O
Actual	O
numbers	O
of	O
total	O
CD4	O
+	O
T	O
or	O
CD8	O
+	O
T	O
cells	O
(	O
detected	O
as	O
shown	O
in	O
Supplementary	O
Fig	O
.	O
15b	O
)	O
were	O
also	O
counted	O
in	O
splenocytes	O
obtained	O
from	O
these	O
mice	O
.	O

Error	O
bar	O
:	O
s	O
.	O
d	O
.	O

(	O
n	O
=	O
5	O
per	O
group	O
).	O

Asterisks	O
indicate	O
statistical	O
significance	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
).	O

(	O
a	O
)	O
DR6	O
+	O
CD4	O
+	O
cells	O
of	O
24	O
-	O
week	O
-	O
old	O
female	O
BWF1	O
mice	O
were	O
stained	O
with	O
PE	O
-	O
conjugated	O
anti	O
-	O
Bcl6	O
or	O
isotype	O
matched	O
control	O
Ab	O
.	O

The	O
antibody	O
specific	O
signals	O
of	O
the	O
cells	O
are	O
shown	O
in	O
histogram	O
.	O

(	O
b	O
)	O
7AAD	O
â	O
CD19	O
â	O
CD4	O
+	O
splenocytes	O
obtained	O
from	O
the	O
indicated	O
mice	O
were	O
analysed	O
on	O
CXCR5	O
versus	O
PD1	O
dot	O
plots	O
for	O
recognizing	O
Tfh	O
(	O
PD1high	O
CXCR5high	O
)	O
and	O
pre	O
-	O
Tfh	O
(	O
PD1int	O
CXCR5int	O
)	O
or	O
non	O
-	O
Tfh	O
(	O
PD1	O
â	O
CXCR5	O
â	O
)	O
cells	O
.	O

(	O
c	O
)	O
The	O
Tfh	O
cell	O
populations	O
of	O
24	O
-	O
week	O
-	O
old	O
female	O
BWF1	O
mice	O
were	O
sorted	O
and	O
then	O
Tnfrsf21	O
mRNA	O
expression	O
in	O
these	O
fractionated	O
cells	O
was	O
analysed	O
by	O
quantitative	O
PCR	O
(	O
qPCR	O
).	O

Error	O
bar	O
:	O
s	O
.	O
d	O
.	O

(	O
n	O
=	O
5	O
per	O
group	O
).	O

(	O
d	O
)	O
Both	O
DR6	O
and	O
CXCR4	O
expressions	O
of	O
the	O
indicated	O
Tfh	O
cell	O
populations	O
that	O
were	O
detected	O
as	O
in	O
b	O
are	O
also	O
shown	O
.	O

For	O
detecting	O
Tfh	O
cell	O
populations	O
,	O
gate	O
strategy	O
that	O
was	O
shown	O
in	O
Supplementary	O
Fig	O
.	O
15c	O
was	O
used	O
in	O
b	O
â	O
d	O
.	O

(	O
a	O
;	O
left	O
panel	O
)	O
Total	O
splenocytes	O
of	O
B6	O
mice	O
were	O
stained	O
with	O
biotinylated	O
murine	O
DR6	O
-	O
Fc	O
plus	O
allophycocyanin	O
-	O
conjugated	O
streptavidin	O
.	O

(	O
upper	O
right	O
panel	O
)	O
Cells	O
bound	O
to	O
DR6	O
-	O
Fc	O
among	O
live	O
singlet	O
splenocytes	O
were	O
analysed	O
on	O
FSC	O
versus	O
SSC	O
dot	O
plots	O
.	O

(	O
lower	O
right	O
panel	O
)	O
The	O
gating	O
shown	O
in	O
the	O
FSC	O
versus	O
SSC	O
dot	O
plot	O
is	O
also	O
schematically	O
explained	O
.	O

(	O
b	O
)	O
Total	O
splenocytes	O
were	O
also	O
stained	O
with	O
DR6	O
-	O
Fc	O
and	O
antibody	O
for	O
detecting	O
the	O
indicated	O
cell	O
type	O
.	O

(	O
c	O
)	O
A20	O
or	O
DO11	O
.	O
10	O
-	O
T	O
cells	O
were	O
stained	O
with	O
DR6	O
-	O
Fc	O
.	O

DR6	O
-	O
Fc	O
specific	O
fluorescent	O
intensity	O
of	O
these	O
cell	O
lines	O
is	O
shown	O
.	O

(	O
d	O
)	O
DO11	O
.	O
10	O
-	O
T	O
cells	O
transfected	O
with	O
a	O
cDNA	O
library	O
derived	O
from	O
A20	O
cells	O
were	O
stained	O
with	O
DR6	O
-	O
Fc	O
.	O

The	O
transfectants	O
bound	O
to	O
DR6	O
-	O
Fc	O
were	O
collected	O
by	O
four	O
rounds	O
of	O
sorting	O
and	O
expansion	O
.	O

(	O
e	O
)	O
After	O
the	O
fifth	O
round	O
of	O
sorting	O
,	O
the	O
cDNA	O
library	O
inserted	O
in	O
genomic	O
DNA	O
of	O
the	O
selected	O
transfectants	O
was	O
isolated	O
as	O
a	O
single	O
cDNA	O
fragment	O
(â¼	O
3	O
,	O
000	O
bp	O
).	O

(	O
f	O
)	O
Intensity	O
of	O
DR6	O
-	O
Fc	O
staining	O
on	O
DO11	O
.	O
10	O
-	O
T	O
cells	O
ectopically	O
expressing	O
Syndecan	O
-	O
1	O
of	O
mouse	O
(	O
mSdc1	O
)	O
or	O
human	O
(	O
hSdc1	O
)	O
or	O
empty	O
plasmid	O
.	O

(	O
g	O
)	O
Endogenous	O
syndecan	O
-	O
1	O
of	O
A20	O
cells	O
was	O
precipitated	O
with	O
the	O
indicated	O
Fc	O
-	O
fusion	O
proteins	O
and	O
detected	O
as	O
described	O
in	O
Methods	O
section	O
.	O

WT	O
means	O
Fc	O
protein	O
fused	O
with	O
the	O
extracellular	O
region	O
of	O
DR6	O
wild	O
type	O
,	O
ÎCRD1	O
means	O
the	O
fusion	O
protein	O
lacking	O
CRD1	O
,	O
ÎCRD2	O
,	O
lacking	O
CRD2	O
,	O
ÎCRD3	O
,	O
lacking	O
CRD3	O
or	O
ÎCRD4	O
,	O
lacking	O
CRD4	O
.	O

(	O
h	O
)	O
DO11	O
.	O
10	O
-	O
T	O
cells	O
were	O
transfected	O
with	O
the	O
indicated	O
reporter	O
plasmid	O
with	O
reference	O
plasmid	O
.	O

The	O
cells	O
were	O
then	O
stimulated	O
with	O
the	O
indicated	O
combination	O
of	O
recombinant	O
syndecan	O
-	O
1	O
protein	O
(	O
recSdc1	O
,	O
30	O
nM	O
)	O
and	O
anti	O
-	O
CD3	O
Ab	O
(	O
10	O
Î¼g	O
ml	O
â	O
1	O
).	O

Six	O
hours	O
after	O
the	O
stimulation	O
,	O
reporter	O
activities	O
of	O
the	O
cells	O
were	O
assessed	O
.	O

Error	O
bar	O
:	O
s	O
.	O
d	O
.	O

(	O
n	O
=	O
3	O
per	O
group	O
).	O

(	O
i	O
)	O
Parental	O
DO11	O
.	O
10	O
-	O
T	O
or	O
its	O
DR6	O
-	O
knockout	O
clone	O
(	O
G510	O
-	O
8	O
-	O
7	O
or	O
G510	O
-	O
10	O
-	O
4	O
)	O
was	O
stimulated	O
as	O
described	O
in	O
h	O
.	O

Twelve	O
hours	O
after	O
the	O
stimulation	O
,	O
IL	O
-	O
2	O
production	O
of	O
the	O
cells	O
was	O
assessed	O
as	O
described	O
in	O
Methods	O
section	O
.	O

Error	O
bar	O
:	O
s	O
.	O
d	O
.	O

(	O
n	O
=	O
3	O
per	O
group	O
).	O

Details	O
of	O
the	O
DR6	O
knock	O
out	O
single	O
cell	O
clones	O
is	O
also	O
shown	O
in	O
Supplementary	O
Fig	O
.	O
1c	O
,	O
d	O
.	O

Asterisks	O
or	O
NS	O
in	O
each	O
panel	O
indicate	O
statistical	O
significance	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
)	O
or	O
not	O
significance	O
,	O
respectively	O
.	O

(	O
a	O
â	O
e	O
)	O
Spleens	O
were	O
isolated	O
from	O
24	O
-	O
week	O
-	O
old	O
female	O
BWF1	O
,	O
NZB	O
or	O
B6	O
mice	O
.	O

Splenic	O
cryosections	O
obtained	O
from	O
the	O
BWF1	O
(	O
a	O
)	O
or	O
NZB	O
(	O
b	O
)	O
mice	O
were	O
stained	O
by	O
anti	O
-	O
GL7	O
(	O
left	O
panel	O
)	O
and	O
syndecan	O
-	O
1	O
(	O
right	O
panel	O
)	O
specific	O
antibodies	O
.	O

Additional	O
anti	O
-	O
CD4	O
Ab	O
staining	O
was	O
also	O
used	O
for	O
identifying	O
the	O
border	O
between	O
B	O
and	O
T	O
cell	O
zone	O
.	O

Representative	O
images	O
of	O
at	O
least	O
3	O
independent	O
fields	O
per	O
slide	O
are	O
shown	O
.	O

B	O
,	O
B	O
cell	O
zone	O
;	O
T	O
,	O
T	O
cell	O
zone	O
.	O

Dashed	O
line	O
indicates	O
the	O
border	O
between	O
each	O
region	O
.	O

Bar	O
=	O
100	O
Î¼m	O
.	O

(	O
c	O
)	O
GL7	O
+	O
CD19	O
+	O
and	O
GL7	O
â	O
CD19	O
+	O
B	O
cell	O
populations	O
obtained	O
from	O
the	O
indicated	O
mice	O
were	O
detected	O
by	O
flow	O
cytometry	O
with	O
the	O
gate	O
strategy	O
that	O
is	O
shown	O
in	O
Supplementary	O
Fig	O
.	O
15d	O
.	O

The	O
expression	O
levels	O
of	O
syndecan	O
-	O
1	O
(	O
upper	O
panel	O
)	O
and	O
CD19	O
(	O
lower	O
panel	O
)	O
on	O
the	O
detected	O
B	O
cell	O
populations	O
were	O
shown	O
.	O

Error	O
bar	O
:	O
s	O
.	O
d	O
.	O

(	O
n	O
=	O
3	O
for	O
B6	O
,	O
5	O
for	O
NZB	O
,	O
5	O
for	O
BWF1	O
per	O
group	O
).	O

(	O
d	O
)	O
Mean	O
number	O
(	O
upper	O
panel	O
)	O
or	O
percentage	O
(	O
lower	O
)	O
of	O
the	O
GL7	O
+	O
CD19	O
+	O
GC	O
B	O
cell	O
in	O
live	O
total	O
splenocytes	O
obtained	O
from	O
the	O
indicated	O
mice	O
.	O

Error	O
bar	O
:	O
s	O
.	O
d	O
.	O

(	O
n	O
=	O
3	O
for	O
B6	O
,	O
5	O
for	O
NZB	O
,	O
5	O
for	O
BWF1	O
per	O
group	O
).	O

(	O
e	O
)	O
The	O
number	O
(	O
upper	O
panel	O
)	O
or	O
percent	O
(	O
lower	O
)	O
of	O
pre	O
-	O
Tfh	O
(	O
left	O
)	O
or	O
Tfh	O
cells	O
(	O
right	O
)	O
of	O
live	O
total	O
splenocytes	O
from	O
the	O
indicated	O
mice	O
are	O
also	O
analysed	O
with	O
the	O
gate	O
strategy	O
shown	O
in	O
Supplementary	O
Fig	O
.	O
15c	O
.	O

Error	O
bar	O
:	O
s	O
.	O
d	O
.	O

(	O
n	O
=	O
5	O
per	O
group	O
).	O

(	O
f	O
)	O
CD3	O
+	O
CD4	O
+	O
PD1high	O
/	O
int	O
CXCR5high	O
/	O
int	O
CXCR4	O
+	O
cells	O
were	O
isolated	O
from	O
24	O
-	O
week	O
-	O
old	O
female	O
BWF1	O
mice	O
.	O

The	O
cells	O
were	O
stimulated	O
with	O
the	O
indicated	O
combinations	O
of	O
recSdc1	O
(	O
30	O
nM	O
),	O
anti	O
-	O
CD3	O
Ab	O
(	O
10	O
Î¼g	O
ml	O
â	O
1	O
)	O
and	O
anti	O
-	O
CD28	O
Ab	O
(	O
10	O
Î¼g	O
ml	O
â	O
1	O
).	O

Seventy	O
-	O
two	O
hours	O
after	O
the	O
indicated	O
stimulations	O
,	O
Il	O
-	O
21	O
mRNA	O
production	O
in	O
the	O
cells	O
was	O
analysed	O
by	O
qPCR	O
.	O

Error	O
bar	O
:	O
s	O
.	O
d	O
.	O

(	O
n	O
=	O
3	O
per	O
group	O
).	O

ND	O
,	O
not	O
detected	O
.	O

Asterisks	O
in	O
each	O
panel	O
indicate	O
statistical	O
significance	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
).	O

(	O
a	O
)	O
Effect	O
of	O
25	O
-	O
1	O
Ab	O
(	O
25	O
-	O
1	O
)	O
or	O
nonspecific	O
rat	O
IgG	O
(	O
ctrl	O
-	O
IgG	O
;	O
10	O
Î¼g	O
ml	O
â	O
1	O
)	O
administration	O
on	O
Il	O
-	O
21	O
production	O
of	O
CD3	O
+	O
CD4	O
+	O
PD1high	O
/	O
int	O
CXCR5high	O
/	O
int	O
CXCR4	O
+	O
cells	O
was	O
assessed	O
as	O
described	O
in	O
Fig	O
.	O
4f	O
.	O

(	O
b	O
â	O
d	O
)	O
15	O
-	O
week	O
-	O
old	O
female	O
BWF1	O
mice	O
were	O
intraperitoneally	O
administered	O
nonspecific	O
control	O
rat	O
IgG	O
(	O
ctrl	O
-	O
IgG	O
)	O
or	O
25	O
-	O
1	O
Ab	O
(	O
300	O
Î¼g	O
per	O
mouse	O
every	O
2	O
days	O
,	O
from	O
15	O
to	O
27	O
weeks	O
old	O
;	O
n	O
=	O
8	O
per	O
group	O
).	O

(	O
b	O
)	O
anti	O
-	O
dsDNA	O
Ab	O
production	O
in	O
sera	O
of	O
these	O
mice	O
was	O
assessed	O
by	O
ELISA	O
.	O

Error	O
bar	O
:	O
s	O
.	O
d	O
.	O

(	O
n	O
=	O
8	O
per	O
group	O
).	O

(	O
c	O
)	O
Percentages	O
of	O
proteinuria	O
positive	O
(>	O
100	O
mg	O
protein	O
per	O
dl	O
)	O
mice	O
in	O
each	O
group	O
are	O
shown	O
(	O
P	O
=	O
0	O
.	O
0314	O
by	O
Gray	O
test	O
).	O

(	O
d	O
)	O
The	O
survival	O
rate	O
of	O
these	O
groups	O
is	O
also	O
shown	O
(	O
P	O
=	O
0	O
.	O
0251	O
by	O
Log	O
-	O
rank	O
test	O
).	O

(	O
e	O
â	O
i	O
)	O
Twenty	O
-	O
four	O
-	O
week	O
-	O
old	O
proteinuria	O
-	O
positive	O
female	O
BWF1	O
mice	O
were	O
treated	O
as	O
described	O
above	O
(	O
until	O
32	O
weeks	O
old	O
)	O
(	O
n	O
=	O
4	O
per	O
group	O
).	O

Two	O
days	O
after	O
the	O
last	O
administration	O
,	O
frequency	O
of	O
DR6	O
+	O
cells	O
in	O
CD4	O
+	O
T	O
cells	O
(	O
e	O
),	O
GL7	O
+	O
GC	O
B	O
cell	O
in	O
B220	O
+	O
B	O
cells	O
(	O
f	O
)	O
or	O
syndecan	O
-	O
1high	O
B220	O
â	O
plasma	O
cells	O
in	O
live	O
total	O
splenocytes	O
(	O
g	O
)	O
obtained	O
from	O
these	O
mice	O
was	O
assessed	O
by	O
flow	O
cytometry	O
.	O

Gate	O
strategies	O
that	O
were	O
used	O
for	O
identifying	O
each	O
cell	O
population	O
were	O
shown	O
in	O
Supplementary	O
Fig	O
.	O
15a	O
â	O
e	O
.	O

Error	O
bar	O
:	O
s	O
.	O
d	O
.	O

(	O
n	O
=	O
4	O
per	O
group	O
).	O

(	O
h	O
)	O
Splenic	O
cryosections	O
obtained	O
from	O
these	O
mice	O
were	O
stained	O
by	O
GL7	O
Ab	O
for	O
detecting	O
GCs	O
(	O
magenta	O
).	O

The	O
sections	O
were	O
also	O
stained	O
by	O
anti	O
-	O
B220	O
Ab	O
(	O
green	O
)	O
for	O
detecting	O
B	O
cell	O
area	O
.	O

Bar	O
,	O
100	O
Î¼m	O
.	O

The	O
results	O
obtained	O
from	O
the	O
other	O
sections	O
are	O
also	O
represented	O
in	O
Supplementary	O
Fig	O
.	O
9	O
.	O

(	O
i	O
)	O
Area	O
of	O
GL7	O
+	O
in	O
each	O
section	O
was	O
also	O
calculated	O
.	O

Error	O
bar	O
,	O
s	O
.	O
d	O
.	O

(	O
n	O
=	O
4	O
â	O
6	O
per	O
section	O
).	O

Asterisks	O
in	O
each	O
panel	O
indicate	O
statistical	O
significance	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
).	O

